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Abstract 
Targeted therapies have begun to be developed and approved in the clinic 
over the past several decades to treat cancers with specific genetic alterations. In 
non-small cell lung cancer (NSCLC), patients harboring EGFR activating mutations 
often respond to the EGFR inhibitors gefitinib/erlotinib, exhibiting down-regulation of 
central oncogenic pathways and dramatic tumor regressions.  Despite initially 
promising results, the vast majority of patients develop resistance to targeted 
therapies.  Thus far, several mechanisms of resistance including T790M mutation in 
EGFR, amplification of the MET receptor tyrosine kinase (RTK), activating mutations 
in downstream signaling molecules, and loss of negative regulators have been 
identified.  As a result, next generation inhibitors and combination therapies continue 
to be developed and tested in the clinic.  
There are still many cases in which the cause of resistance to a particular 
targeted therapy is unknown, or the subset of patients most likely to benefit has not 
been identified.  This thesis describes the ability of the MET ligand, HGF, to activate 
PI3K signaling and cause gefitinib resistance in EGFR-driven cancers. In addition, 
detection of a preexisting subpopulation of MET amplified cells (present before 
treatment with an EGFR inhibitor) is shown to successfully predict the development 
of MET amplification as a resistance mechanism. These results suggest that it may 
be possible to prospectively identify patients who will benefit from combined 
MET/HGF and EGFR inhibitors as initial therapies.  Further, this thesis highlights the 
iv 
importance of both PI3K/AKT and MEK/ERK signaling as drivers of cell proliferation 
and viability, and describes a novel feedback network regulating these pathways.  In 
multiple cancer models, treatment with a single agent MEK inhibitor leads to 
feedback up-regulation of ERBB3/PI3K/AKT signaling.  The mechanism for this 
feedback involves loss of an inhibitory threonine phosphorylation in the conserved 
juxtamembrane domains of EGFR and HER2 following MEK inhibition, which leads 
to increased ERBB receptor activation.  These results further elucidate the complex 
feedback networks that regulate signaling in cancer cells, and suggest possible 
limitations for the efficacy of single agent RAF/MEK pathway inhibitors.  Collectively, 
this work describes multiple resistance mechanisms to kinase inhibitors, and 
suggests new biomarkers to define those patients who are likely to benefit from 
specific targeted therapies. 
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1Chapter 1- Background 
1.1 History of Cancer 
Cancer is a disease characterized by abnormal growth of cells in the body.  
These malignant cells exhibit uncontrolled proliferation and resistance to cell death 
signals, and are capable of invasion and metastasis.  There are hundreds of cancer 
types listed by the National Cancer Institute, traditionally characterized by the 
location in the body where the primary malignancy originated. In the past decade 
cancer has surpassed heart disease as the leading cause of death in the United 
States (Jemal et al., 2010). In 2010 there were approximately 1.5 million new cases 
of cancer diagnosed in the United States and over 500,000 deaths.  Of these, lung 
cancer is by far the leading cause of cancer death in both men and women (Jemal et 
al., 2010). 
In approximately 2500 BC, an Egyptian physician gave the first known 
description of cancer, writing of a patient with “bulging tumors of the 
breast…swellings on the breast, large, spreading and hard”.  Under a section titled 
“Therapy”, the physician wrote, “There is none”. Two thousand years later in 400 BC, 
the first word for cancer, karkinos (the Greek word for “crab”) appeared in the 
medical literature.  These early cancers were mostly large superficial tumors and 
were initially treated with crude surgical techniques often leading to massive 
infections.  During this period Hippocrates noted that cancer was “best left untreated, 
since patients live longer that way” (Mukherjee, 2010).    
Unfortunately, unlike other widespread diseases including heart disease, 
progress in the development of effective cancer therapies has thus far been 
markedly slow.  In many cases, particularly if the disease is not detected early, the 
long-term prognosis remains poor.  Current therapies typically offer only short-term 
remissions, and these treatments are commonly associated with significant side 
2effects.  Just in the last few decades have we begun to understand cancer at the 
genetic level.  We have started to develop promising therapies that target these 
genetic lesions, which demonstrate improved specificity and less toxicity, and we are 
moving in the direction of personalized cancer medicine.
1.2 Evolution of Cancer Therapies 
Surgical removal of cancerous tumors was the first treatment developed in an 
attempt to cure patients of this disease, and it has remained one of the most effective 
cancer therapies, particularly for localized solid tumors. However, for non-solid 
tumors or in cases where the cancer has already metastasized or is difficult to 
remove, surgery is relatively ineffective.   In the late 19th century, cancer researchers 
discovered the ability of X-rays to selectively kill rapidly dividing cells and began to 
test radiation therapies in cancer patients.  Today radiation is also still used in the 
clinic, despite toxic side effects.  In 1948 Sidney Farber treated children with acute 
lymphoblastic leukemia with derivatives of a new drug compound called an antifolate, 
a chemical that blocks the growth of white blood cells, and achieved the first cancer 
remissions in response to a chemotherapeutic (Farber and Diamond, 1948).  At the 
same time, scientists began using DNA damaging agents, initially designed as war 
gasses, to target and destroy rapidly dividing cancer cells.  Successful trials using 
multiple combinations of new chemotherapeutics continued into the 1950s, and in 
fact, several of these drugs are still used as the standard of care for cancer patients 
today.  However, these therapies are often incredibly toxic, and some patients are 
forced to withdraw from treatment due to the severity of the side effects (Mukherjee, 
2010).   
 In addition to the discovery of radiation and chemotherapy, significant 
progress has also been made in terms of cancer prevention.  Numerous clinical trials 
3have been carried out over the past century to identify environmental causes of 
cancer.  In 1948 two independent groups reached the same clear conclusion 
following from their respective trials: cigarette smokers are significantly more likely to 
develop lung cancer (Doll and Hill, 1950; Wynder and Graham, 1950).  In the 
following decades, these studies were repeated on larger scales and eventually led 
to increased public awareness of smoking-associated cancer risk.  Today, these 
efforts are finally contributing to a decreased incidence of lung cancer in men and 
similar trends are projected to follow in women (Jemal et al., 2010). 
We began to understand the biology and signaling within the cancer cell in 
the late 20th century.  In the 1970s, Michael Bishop and Harold Varmus at UCSF 
began to look for variations of the viral oncogene v-src in normal cells (Stehelin et al., 
1976), and in 1989 they won the Nobel Prize for their discovery of the cellular origin 
of retroviral oncogenes. Soon after the characterization of src, the ras oncogene was 
discovered in the Weinberg laboratory in Cambridge, MA and the results were 
published with two other groups in 1982 (Der et al., 1982; Parada et al., 1982; Shih 
and Weinberg, 1982).  These seminal discoveries provided the first real 
understanding of the proteins and pathways that are often deregulated in cancer, 
and lead to the identification of new cellular targets. 
Once specific oncogenes began to be identified, pharmaceutical companies 
started to develop drugs that could inhibit these proteins directly, thus targeting the 
growth and proliferation of cancer cells much more specifically while causing 
relatively few off-target effects in normal tissues.  The first targeted cancer therapy 
was developed at Genentech in collaboration with Dennis Slamon, an oncologist at 
UCSF.  Herceptin (Trastuzumab) is a humanized monoclonal antibody against the 
HER2 receptor tyrosine kinase, which is amplified in a subset of breast cancers 
(Bazell, 1998).  Trials using this new targeted therapy were first performed in breast 
4cancer patients (with tumors expressing high levels of HER2) in the early 1990s with 
very promising results.  The first tyrosine kinase inhibitor (TKI), imatinib (Gleevec), 
was developed by Novartis in collaboration with Brian Druker and Charles Sawyers 
to target the hyper-activated BCR-ABL fusion protein, as well as c-KIT and PDGFR 
kinases.  Gleevec gained FDA approval in 2001 for treatment of patients with chronic 
myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), and 
remains one of the greatest success stories for targeted cancer therapy (Demetri et 
al., 2002; Druker et al., 2001). Over the past twenty years, dozens of new targeted 
therapies, including monoclonal antibodies and small molecule kinase inhibitors, 
have been developed and tested in the clinic. However, there are still many cancers 
in which the target or targets driving oncogenesis are unidentified, or in which there 
are currently no effective drugs available to block the target.  Furthermore, numerous 
challenges involving specificity, drug delivery and pharmacokinetics, and drug 
resistance remain unsolved.   
1.3 The PI3K/AKT and RAF/MEK/ERK Signaling Pathways
 The phosphatidylinositol 3-kinase (PI3K) and RAF/MEK/ERK mitogen-
activated protein kinase (MAPK) signaling pathways have been identified as central 
oncogenic drivers in a wide range of cancers. These signaling cascades are made 
up of kinases, enzymes that transfer phosphate groups from high-energy donors 
such as ATP to specific substrates, and converge on downstream effectors that 
regulate apoptosis, cell growth, metabolism, proliferation, and metastasis.   
 Upstream of both the PI3K/AKT and RAF/MEK/ERK signaling pathways are 
trans-membrane receptor tyrosine kinases (RTKs), which receive extra-cellular 
signals and transmit these signals into the cell, activating downstream pathways 
through phosphorylation cascades.  The ERBB family of receptors is comprised of 
5four members; EGFR (ERBB1), HER2 (ERBB2, neu), HER3 (ERBB3), and HER4 
(ERBB4) (Zhang et al., 2007) (Figure 1). Each of these receptors, with the exception 
of HER2, binds extracellular ligands and undergoes a conformational change to form 
asymmetric dimers. Within these active dimers, the kinase domain of one of the 
receptors trans- and auto-phosphorylates tyrosine residues on the C-terminal tails of 
both receptors.  Adaptors and signaling molecules are then recruited to bind these 
phosphorylated tyrosine residues, leading to activation of downstream pathways.  
The ERBB3 receptor is unique in that it is kinase-dead and serves only as an 
inactive binding partner for other RTKs; however, ERBB3 contains several PI3K 
binding sites and is commonly used as an adaptor to directly activate PI3K/AKT 
signaling (Engelman et al., 2005). 
  
6The PI3K pathway has been shown in the laboratory and in the clinic to be 
critical for the viability of many cancers (Cantley, 2002; Engelman, 2009; Lee et al., 
2007).  The class I phosphoinositide 3-kinase (PI3K) is a heterodimer composed of a 
p110 catalytic subunit and a p85 regulatory subunit.  In unstimulated cells, PI3K 
exists in the cytoplasm in an inactive conformation.  However, when receptors or 
adaptor proteins become activated, two p85 Src homology 2 (SH2) domains bind to 
phosphorylated tyrosine residues at the cell membrane.  As a result, PI3K is 
recruited to the cell membrane and p110 is released from p85 inhibition, allowing 
for the phosphorylation of the membrane lipid phosphatidylinositol 4,5-bisphosphate 
(PIP2) to produce phosphatidylinositol 3,4,5-trisphosphate (PIP3)  (Figure 2).  This 
leads to the recruitment and activation of several downstream signaling effectors,  
7including AKT, which is activated through phosphorylation at two serine/threonine 
sites, S473 and T308.  AKT itself is a serine/threonine kinase that has been widely 
implicated in cancers and regulates multiple pathways that control cell growth, 
proliferation, and survival (Brugge et al., 2007; Carpten et al., 2007; Engelman et al., 
2006a) (Figure 3). 
The RAF/MEK/ERK signaling pathway has also been shown to be aberrantly 
activated in a wide range of human cancers (Davies et al., 2002; Malumbres and 
Barbacid, 2003; Montagut and Settleman, 2009).  Signaling through this pathway is  
8initiated through activation of RAS family GTPases, by RTKs or through direct 
mutation, at the cell membrane.  Active RAS then initiates a signaling cascade in  
which RAF kinases phosphorylate MEK kinases, which in turn phosphorylate  
extracellular related kinases (ERK1 and ERK2), leading to activation of multiple 
downstream effectors including those regulating cell proliferation and apoptosis.   
One of the major effectors of both PI3K/AKT and RAF/MEK/ERK signaling is 
the mammalian target of rapamycin complex 1 (mTORC1), which includes the the 
serine/threonine kinase mTOR.  Depending on the particular cancer type, the 
mTORC1 complex integrates signals from a combination of the PI3K/AKT and 
MEK/ERK pathways, as well as nutrient, growth factor, and energy sensing inputs; 
and controls numerous protein synthesis and cell growth pathways (Huang and 
Manning, 2008; Kim et al., 2002; Manning and Cantley, 2007) (Figure 3). 
Multiple negative regulators are in place to control these central oncogenic 
pathways regulating cell cycle, growth, and survival. The PTEN phosphatase 
terminates PI3K signaling by dephosphorylating PIP3 (Li et al., 1997; Maehama and 
Dixon, 1998).  A collection of additional phosphatases de-phosphorylate RTKs, 
adaptor molecules, and kinases—including AKT and RAF—in order to abrogate 
signaling and minimalize flux through a particular pathway.  The ubiquitin 
proteasome system mediates protein degradation and thus can regulate protein 
expression levels.  Finally, there are multiple feedback loops that have evolved to 
actively control cellular signaling, and these complex feedbacks can complicate the 
effects of specific inhibitors in certain cancer models.  
91.4 Targeted Cancer Therapies  
Over the past few decades, specific mutation, over-expression, or deletion of 
key components of the PI3K/AKT and MAPK signaling pathways have been 
identified and linked to tumorigenesis.  Activating mutations in EGFR have been 
shown to drive central oncogenic pathways in non-small cell lung cancer (NSCLC) 
(Lynch et al., 2004; Paez et al., 2004; Rusch et al., 1993), and amplification of the 
HER2 and MET receptor tyrosine kinases has been associated with certain forms of 
cancer including breast, gastric, and NSCLC (Engelman et al., 2007b; Slamon et al., 
1987; Smolen et al., 2006).  Mutations in AKT and the PIK3CA gene encoding the 
p110 subunit of PI3K have also been found to occur frequently in cancers (Brugge 
et al., 2007; Huang et al., 2007; Samuels et al., 2004).  Activating RAS mutations are 
the most common mutations observed thus far in human cancers (Malumbres and 
Barbacid, 2003), and oncogenic mutations and amplifications of RAF and MEK are 
also common (Davies et al., 2002; Montagut and Settleman, 2009).  Finally, loss of 
negative regulators, including PTEN deletions, has been shown to occur frequently 
(Li et al., 1997).  Identification of the central pathways regulating tumorgenesis and 
the key oncogenic events responsible for transformation has allowed for the 
development of specific targeted cancer therapies.  Since Herceptin was first used in 
patients with HER2-positive breast cancer in the early 1990s, many additional targets 
have been identified and validated, and dozens of new drugs have been developed 
and tested in the clinic.   
Kinases are relatively accessible targets; a number of therapeutics including 
small molecule ATP mimetics have been successfully developed to inhibit kinase 
activity.  Notable examples include the clinically approved EGFR inhibitors gefitinib 
(Iressa) and erlotinib (Tarceva), and the BCR-ABL kinase inhibitor imatinib 
(Gleevec). Numerous drugs targeting additional RTKs—as well as inhibitors of PI3K, 
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mTOR, AKT, MEK, and RAF—are currently under clinical development and are 
being tested both as mono-therapies and in combinations. 
Therapies targeting non-kinases are also being explored in the clinic.  
Therapeutic monoclonal antibodies that target extracellular proteins represent a 
growing class of drugs.  As discussed above, Herceptin is a HER2 monoclonal 
antibody effective in HER2-positive breast cancers (Baselga, 2001a). The EGFR 
monoclonal antibody Cetuximab has also been approved clinically (Baselga, 2001a; 
Baselga, 2001b).  Antibodies targeting the kinase dead ERBB3 receptor scaffold are 
actively undergoing pre-clinical development (Schoeberl et al., 2010).  Finally, 
subsets of drugs targeting additional pathways upon which cancer cells depend 
heavily are being explored for the inhibition of central processes including 
angiogenesis, metastasis, and apoptosis. 
Most targeted therapies already provide a significant advantage over the 
traditional, relatively toxic chemotherapy and radiation therapies; however, despite 
their successful clinical development thus far, there are still a number of challenges 
that remain. First, limiting the number and severity of dose-limiting side effects 
incurred by normal cells is essential, and these challenges will only increase as more 
patients require treatment with multiple drug combinations.  Second, substantial 
efforts are being made to achieve optimal pharmacokinetic and pharmakodynamic 
properties for new drugs, including designing drugs that are orally available, and 
determining which dosing schedules are most effective.  Third, there are still several 
cancers in which the oncogenic driver or drivers have not yet been identified or in 
which there is not yet a drug available to reliably and selectively hit a particular 
target.  Finally, despite often dramatic initial responses following treatment with 
targeted therapies, patients develop resistance almost universally.  Efforts to further 
11
elucidate the signaling pathways and feedback networks that are active in cancers 
with acquired resistance will be a focal point of this thesis.   
1.5 Resistance to EGFR Targeted Therapies 
 Non-small cell lung cancer (NSCLC) patients with EGFR activating mutations 
often exhibit exquisite sensitivity to the EGFR tyrosine kinase inhibitors gefitinib and 
erlotinib (Asahina et al., 2006; Inoue et al., 2006; Sequist et al., 2008) (Figure 4A).  
However, the vast majority of these patients develop resistance despite promising 
initial responses (Figure 4B), typically within 12 months (Engelman and Settleman, 
2008; Sharma et al., 2007).  In EGFR mutant NSCLC, a secondary T790M mutation 
in the ATP binding pocket of EGFR occurs in about 50% of resistance cases,  
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allowing the EGFR kinase to remain active in the presence of drug (Balak et al., 
2006; Kobayashi et al., 2005; Pao et al., 2005).  Recently, irreversible EGFR 
inhibitors have been developed that bind covalently to the ATP binding pocket and 
are effective in inhibiting T790M mutant EGFR (Zhou et al., 2009; Zhou et al., 2011).  
Similar secondary mutations in the target kinase, often affecting this “gatekeeper” 
residue, are also common in other forms of cancer (Katayama et al., 2011; O'Hare et 
al., 2009).  In addition to direct mutation of the target kinase, activation of parallel 
RTKs has also been shown to cause resistance to EGFR targeted therapies.  For 
example, amplification of the MET receptor occurs in approximately 20% of NSCLC 
patients with acquired gefitinib resistance (Engelman et al., 2007b).  Activation of 
IGFR signaling through loss of IGF binding proteins has also been shown to cause 
resistance to EGFR targeted therapies (Guix et al., 2008).   
In the majority of cases, resistant cancers re-activate downstream oncogenic 
pathways including PI3K/AKT and RAF/MEK/ERK.  Combinations of PI3K inhibitors, 
mTOR inhibitors, BRAF inhibitors, and MEK inhibitors are currently being tested in a 
variety of human cancers including NSCLC.  However, the ultimate success of these 
combination therapies may be limited by toxicity and resistance. There is a pressing 
need for the development of more effective diagnostic tools and the identification of 
new biomarkers will allow for more efficient clinical trials. The discovery of novel 
therapeutics and a more complete understanding of the signaling pathways and 
feedback networks that become re-activated in resistant cancers will ultimately 
encourage the shift towards more effective and lasting personalized targeted cancer 
therapies. 
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Chapter 2- Ligand mediated resistance1
2.1 Abstract 
MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung 
cancers, and causes resistance to EGFR kinase inhibitors. My colleagues and I 
demonstrate that activation of MET by its ligand, hepatocyte growth factor (HGF), 
also activates downstream signaling pathways and rescues several EGFR-driven 
cancer cell lines from TKI sensitivity in a dose dependent manner.  However, when 
MET is activated via ligand cells use GAB1 to activate PI3K.  This is in contrast to 
MET amplified cancers, which use ERBB3 to activate PI3K.  Further, we show that 
HGF does not activate PI3K signaling in HER2-driven cell line models, and that IGF 
ligand is less potent than HGF in promoting resistance.  In non-small cell lung cancer 
(NSCLC) patient samples, high levels of HGF expression correlated significantly with 
resistance to EGFR inhibitors.  These results suggest that an additional subset of 
patients, those with high HGF expression but normal MET copy number, may benefit 
from treatment with combined MET and EGFR inhibitors.  This study also highlights 
the need for the development of anti-HGF targeted therapies. 
2.2 Introduction 
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 
gefitinib and erlotinib are effective clinical therapies for advanced non-small cell lung 
cancer (NSCLC) patients with EGFR activating mutations (Asahina et al., 2006; 
Inoue et al., 2006; Paz-Ares et al., 2006; Sequist et al., 2008; Tamura et al., 2008). A 
recent phase III clinical trial demonstrated that patients with EGFR mutant NSCLC 
had superior outcomes with gefitinib treatment compared to standard first line 
                                                
1 Excerpts and figures from this chapter were published in Turke at al., Cancer Cell, January 
2010. 
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cytotoxic chemotherapy (Mok et al., 2008). However, despite dramatic benefits from 
EGFR TKIs in this genetically defined cohort, all of these patients ultimately develop 
resistance (referred to as acquired resistance herein) to gefitinib and erlotinib.  
In EGFR mutant lung cancers over 50% of resistance cases are due to the 
occurrence of a secondary T790M mutation in EGFR.  Amplification of the MET 
receptor has also been shown to maintain ERBB3/PI3K/AKT signaling in the 
presence of gefitinib (reviewed in (Engelman and Janne, 2008)) and cause 
resistance to EGFR targeted therapies in approximately 20% of NSCLC patients 
(Engelman et al., 2007b).  In fact, clinical trials using combined EGFR and MET 
inhibitors in NSCLC patients with acquired resistance to gefitinib/erlotinib are 
currently underway.  Activation of IGF-1R/IRS-1 signaling through loss of IGF 
binding proteins also drives gefitinib resistance in EGFR wild-type cancer cell lines 
(Guix et al., 2008). Additionally, a recent study suggested that the MET ligand, HGF, 
can promote short-term resistance in two EGFR mutated cancer cell lines (Yano et 
al., 2008).  Both ligand-dependent resistance mechanisms maintain PI3K/AKT 
activation despite EGFR inhibition.  However, differences between IGF and HGF 
ligand-driven resistance in terms of potency and activation of downstream signaling 
pathways have yet to be thoroughly examined.  
MET encodes a trans-membrane RTK for the hepatocyte growth factor (HGF) 
and is capable of activating ERBB receptors to drive cell migration, invasion, 
proliferation, survival and angiogenesis (Christensen et al., 2003). MET amplification 
has been detected in gastric and esophageal cancers (Christensen et al., 2003; 
Miller et al., 2006) and cell lines derived from such tumors display ligand-
independent dependence on MET (Smolen et al., 2006). However, it remains 
unknown whether activation of MET by its ligand, HGF, is a mechanism utilized by 
human tumors to develop resistance to ERBB-targeted therapies. 
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In the current study, we evaluated the potency of the MET ligand, HGF, to 
activate downstream PI3K/AKT and MEK/ERK signaling pathways, and promote 
resistance to EGFR TKIs in vitro and in vivo.  We also assessed the potential of the 
IGF ligand to promote resistance.  Finally, we analyzed tumor samples from NSCLC 
patients with acquired resistance to gefitinib and compared HGF expression levels in 
paired pre- and post-treatment tumor samples. The findings from these analyses 
highlight a new cohort of patients, those with high HGF expression but without MET
amplification, that may benefit from combined EGFR and HGF/MET targeted 
therapies. 
2.3 Materials and Methods 
Cell culture and reagents  
 The EGFR mutant NSCLC cell lines HCC827 (del E746_A750), PC-9 (del 
E746_A750) and H1975 (L858R/T790M) have been previously characterized 
(Amann et al., 2005; Engelman et al., 2007a; Engelman et al., 2007b; Mukohara et 
al., 2005; Ono et al., 2004).  The EGFR wild type epidermoid carcinoma cell line 
A431 and head and neck cancer cell line HN11 have been described previously 
(Guix et al., 2008). The HER2 amplified breast cancer cell lines BT-474 and SKBR3 
cells were kind gifts from Dr. Carlos L. Arteaga (Vanderbilt University School of 
Medicine, Nashville, Tennessee).  HCC827 cells were maintained in RPMI 1640 
(Cellgro; Mediatech Inc., Herndon, CA) supplemented with 5% FBS; H1975, PC-9, 
A431 and HN11 cell lines were maintained in RPMI 1640 supplemented with 10% 
FBS.  BT-474 cells were maintained in Dulbecco’s Modification of Eagle’s Medium 
(DMEM) (Cellgro; Mediatech Inc., Herndon, CA) and SKBR3 cells were maintained 
in McCoy’s 5A Medium (Invitrogen, Carlsbad, CA), both supplemented with 10% 
FBS.   
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 Recombinant human HGF and the Quantikine ELISA Kit for quantification of 
HGF in cell culture medium were purchased from R&D Systems (Minneapolis, MN).  
Recombinant human IGF-1 was purchased from Austral Biologicals (San Ramon, 
CA). Gefitinib and lapatinib were obtained from commercial sources (American 
Custom Chemical Corporation and LC Laboratories Woburn, MA). PF00299804, 
PHA-665,752 and PF2341066 were provided by Pfizer (La Jolla, CA).   
Cell viability assays  
 Growth and inhibition of growth was assessed by Syto60 staining 
(Invitrogen).  Cells were fixed with 4% formaldehyde for 20 min at 37oC and 
incubated with a 1:5000 dilution of Syto60 stain for 60 min. Cell density in each well 
was determined with an Odyssey Infrared Imager (LiCor Biosciences), corrected for 
background fluorescence from empty wells and normalized to untreated wells, as 
described previously (Rothenberg et al., 2008). 
 For 72 hour viability assays, cells were seeded in 96-well plates and exposed 
to the indicated TKIs (3.3 nM to 10 M) alone or in combination with the indicated 
concentrations of HGF or IGF ligand. The number of cells used per experiment was 
determined empirically and has been previously established (Mukohara et al., 2005).  
All experimental points were set up in six to twelve wells and all experiments were 
repeated at least three times. The data was graphically displayed using GraphPad 
Prism version 5.0, (GraphPad Software; www.graphpad.com).  The curves were 
fitted using a non-linear regression model with a sigmoidal dose response. 
Antibodies and Western Blotting  
 Cells grown under the previously specified conditions were lysed in the 
following lysis buffer: 20 mM Tris, pH 7.4/150 mM NaCl/1% Nonidet P-40/ 10% 
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glycerol/1 mM EDTA/1 mM EGTA/5 mM sodium pyrophosphate/50 mM NaF/10 nM 
-glycerophosphate/1 mM sodium vanadate/0.5 mM DTT/4 g/ml leupeptin/4 g/ml 
pepstatin/4 g/ml apoprotein/1 mM PMSF. Lysates were centrifuged at 16,000 × g 
for 5 min at 4°C. The supernatant was used for subsequen t procedures. Western 
blot analyses were conducted after separation by SDS/PAGE electrophoresis and 
transfer to nitrocellulose or PVDF membranes.  Immunoblotting was performed 
according to the antibody manufacturer’s recommendations.  Antibody binding was 
detected using an enhanced chemiluminescence system (PerkinElmer, Waltham, 
MA). Anti-phospho-Akt (Ser 473), anti-phospho-ERBB-3 (Tyr-1289), anti-phospho-
p42/44 MAP kinase (Thr 202 Tyr 204), anti-p42/44 MAP kinase, anti-phospho-S6 
ribosomal protein (Ser 335/236), anti-S6 ribosomal protein, anti-phospho MET (Tyr 
1234/1235), anti-MET (25H2), anti-phospho HER2 (Tyr 1211/1222), anti-phospho 
IGF-I receptor (Try 1135/1136), anti-IGFR, and anti-phospho-Tyr-100 antibodies 
were from Cell Signaling Technology (Beverly, MA).  Anti-ERBB3, anti-AKT, anti-
GAB1, and anti-EGFR antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). The phospho-specific EGFR (Tyr1068) antibody was from AbCam 
(Cambridge, MA). The anti-HER2 antibody was from Oncogene Research Products 
now Calbiochem (SanDiego, CA). The anti-p85 antibody used for 
immunoprecipitations was from Millipore (Billerica, MA). Western blots images were 
captured using GeneSnap image acquisition software and analyzed using 
GeneTools manual band quantification (SynGene: www.syngene.com).   
In vivo treatment studies 
 All xenograft studies were performed in accordance with the standards of the 
Institutional Animal Care and Use Committee (IACUC) under a protocol approved by 
the Animal Care and Use Committee of Massachusetts General Hospital. Nude mice 
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(nu/nu; 6-8 weeks old; Charles River Laboratories) were anesthetized using a 2% 
Isoflurane (Baxter) inhalation oxygen mixture. A suspension of 5x106 HCC827-HGF 
cells (in 0.2 ml of PBS) was inoculated subcutaneously into the lower-left quadrant of 
the flank of each mouse. Mice were randomized to 4 treatment groups (n=5 per 
group) once the mean tumor volume reached ~500 mm3. PF2341066 was dissolved 
in sterile water and administered at 25mg/kg/day. Gefitinib was dissolved in 
polysorbite vehile and administered at 150mg/kg/day.  For combination studies oral 
administration of the two agents was separated by 1 hour. Tumors were measured 
twice weekly using calipers, and volume was calculated using the formula (length x 
width2 x 0.52). Mice were monitored daily for body weight and general condition. The 
experiment was terminated when the mean size of either the treated or control 
groups reached 2000 mm3.  
 Tumor volume was analyzed by a mixed linear model, assuming an 
unstructured covariance matrix for the random effects and an AR(1) structure for the 
within-mouse correlation. Volume measurements were transformed into the log scale 
for analysis in order to approximate a linear fit, reflecting the exponential growth of 
tumors. A quadratic effect was included in the model for the HCC827-HGF 
xenografts to account for the initial tumor shrinkage followed by subsequent re-
growth in the treatment group with gefitinib alone.
sRNA transfections and Lentiviral Infections 
 Hs_GAB1_6 HP validated siRNA and AllStars Negative Control siRNA were 
obtained from Qiagen (Valencia, CA).  HCC827 cells were seeded 200K cells/well on 
a 6-well plate in RPMI media without penicillin or streptomycin.  Cells were 
transfected with 50nM siRNA with using 18µL HiPerFect Transfection Reagent 
(Qiagen) in Opti-MEM Reduced Serum Media from Gibco Invitrogen (Frederick, MD) 
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and incubated at 37oC for 48 hours. HGF cDNA was obtained from Open Biosystems 
and cloned into a lentiviral destination vector, pWPI, using the Gateway cloning 
system (Invitrogen), and infections were performed as previously described 
(Rothenberg et al., 2008). 
NSCLC patients 
 Tumor specimens from gefitinib or erlotinib treated patients were obtained 
from the Dana Farber Cancer Institute/Brigham and Women’s Hospital (Boston, MA), 
Massachusetts General Hospital (Boston, MA), the Chinese University (Hong Kong, 
China) and from Guangdong Provincial People's Hospital (Guangzhou, China) under 
Institutional Review Board approved studies. All patients provided written informed 
consent. The presence of an EGFR mutation in each specimen was confirmed by 
exon-specific amplification (exons 18-21), followed by direct sequencing, or using the 
SurveyorTM endonuclease coupled with denaturing HPLC (DHPLC), fractionation and 
sequencing (Janne et al., 2006). The EGFR T790M mutation was detected using 
SurveyorTM endonuclease coupled with DHPLC or an allele specific PCR (Janne et 
al., 2006; Maheswaran et al., 2008). Both methods are capable of detecting the 
EGFR T790M mutation at an allele frequency of 1-5%. HGF immunohistochemistry 
was performed using an anti-HGF 7.2 antibody kindly provided by Dr. George 
Vander Woude at the Van Andel Institute. 
HGF immunohistochemistry 
Immunohistochemistry for HGF protein was performed on positively charged 
glass slides containing 5-micron sections of formalin-fixed, paraffin-embedded tissue.  
Slides were deparaffinized in Hemo-De for 10 min and rinsed (6 washes) into 
absolute ethanol, before endogenous peroxidase was blocked with 1.05% hydrogen 
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peroxide in ethanol for 30 min.  Blocked slides were rinsed in water and microwave 
antigen retrieval was performed in citrate buffer (pH 6.0).  The sections were 
incubated overnight, at room temperature, with primary antibody (mouse monoclonal 
anti-HGF, generously contributed by Dr. George Vander Woude) diluted 1:300 in 
TBS.  After incubation, excess primary antibody was rinsed off with TBS, and the 
sample was washed in TBS with 0.02% BRIJ for 10 min.  Signal was amplified by 
secondary incubation with EnvisionPlus (DAKO, Carpinteria, CA), for 30 min.  Bound 
antibodies were detected by DAB chromogenic (brown) reaction, after 5 min 
incubation. 
 Slides were interpreted by a board-certified anatomic pathologist (NIL), who 
evaluated the percentage of cancer cells with positive cytoplasmic and/or 
membranous staining (0 – 100%), and the modal intensity of the positively-staining 
cells on a scale from 0 to 4+ (Figure 9).  The percentage and the intensity were 
multiplied to give a scoring index ranging from 0 – 400.  For comparison of HGF 
immunohistochemistry results, the HGF scores in paired NSCLC patient specimens 
were compared using the Wilcoxon signed rank test. A one sided p-value was used 
to test the hypothesis that HGF scores were higher in the drug resistant compared to 
the pre-treatment specimens. 
2.4 Results 
HGF activates PI3K/AKT signaling and mediates resistance to EGFR targeted 
therapies 
MET amplification was previously shown to cause gefitinib resistance in 
HCC827 GR cells (Engelman et al., 2007b). Here we investigated whether activation 
of MET signaling by its ligand, HGF, could also cause resistance to gefitinib and 
other ERBB-targeted therapies. In a 72 hour survival assay, HGF induced substantial 
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gefitinib resistance in HCC827 cells that was abolished by the addition of the MET 
inhibitor PHA-665,752 (Figure 5A).  Furthermore, HGF maintained PI3K/AKT, 
mTORC1 and ERK activation in the presence of gefitinib in a dose-dependent 
manner that mirrored its capacity to maintain cell viability (Figures 5B, C). 
We also determined the capacity for HGF to maintain downstream signaling 
and cell viability in other EGFR and HER2 addicted cancers. In cell lines with EGFR
22
exon 19 deletions (HCC827 and PC-9), and an EGFR-driven lung cancer cell line 
carrying the T790M resistance mutation (H1975), HGF restored PI3K/AKT, mTORC1 
and ERK signaling, despite continued EGFR inhibition in the presence of 1µM 
gefitinib or the irreversible EGFR inhibitor PF00299804 (Figure 5D).  HGF also  
rescued each of these cell lines from TKI-induced cell death after 72 hours (Figure 
6A).  In contrast to the EGFR addicted cancers, HGF did not rescue HER2 amplified 
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breast cancer cell lines from the effects of the HER2 TKI lapatinib (Figure 6A), nor 
did it rescue AKT or mTORC1 signaling in either HER2 driven cell line (Figure 5D).  
Thus, the capacity to rescue cell viability appears to strongly correlate with capacity 
to restore downstream signaling, especially along the PI3K/AKT pathway. We 
suspect that HGF had a minimal effect in BT-474 and SKBR3 cells because these 
cell lines have lower levels of MET expression compared to the other EGFR-driven 
cell lines that were tested. 
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To confirm the ability of HGF to induce resistance to EGFR TKIs, we 
introduced the human HGF gene into HCC827 cells (HCC827-HGF). Parental 
HCC827 cells secrete undetectable levels of HGF; however, HCC827-HGF cells 
express HGF protein (Figure 7A) and secrete approximately 70ng/mL HGF into the 
culture medium (data not shown).  Further, HCC827-HGF cells are gefitinib resistant 
(Figure 7B) and maintain PI3K/AKT, ERK and mTOR signaling in the presence of 
gefitinib (Figure 7A); however gefitinib sensitivity is restored with the addition of a 
MET inhibitor (Figure 7B).  
We also evaluated the capacity of HGF to induce gefitinib resistance in vivo
using an HCC827-HGF xenograft model.  We have previously shown that parental 
HCC827 cells demonstrate complete responses to gefitinib in vivo (Engelman et al., 
2006b; Engelman et al., 2007a). However, the HCC827-HGF xenografts 
demonstrated resistance (Figure 7C). Treatment with gefitinib alone was slightly 
more effective than no treatment or treatment with the MET inhibitor PF2341066 
alone, but only the combination of gefitinib and PF2341066 completely inhibited 
tumor growth (p < 0.001; gefitinib vs. gefitinib/PF2341066; Figure 7C). Indeed, 3 out 
of 4 mice were cured after 70 days of combined treatment with no evidence of re-
growth 70 days after stopping treatment. 
IGF is much less potent than HGF in promoting resistance to EGFR TKIs 
Since HGF ligand appeared to be a potent inducer of resistance to RTK 
inhibitors, we compared its efficacy to that of IGF ligand, which we had previously 
found to cause gefitinib resistance in A431 cells (Guix et al., 2008). Although IGF 
exposure led to significant rescue from gefitinib-induced cell death in A431 cells, and 
partial rescue in HN11 EGFR wild-type cells, the other five cell lines tested remained 
sensitive to ERBB inhibition despite the presence of IGF (Figure 6A). Interestingly, in 
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three of those cell lines (BT-474, HCC827 and H1975), IGF was unable to maintain 
PI3K/AKT signaling despite potent activation of IGR-1R (Figure 6B). Of note, IGF 
did not restore ERK phosphorylation in any of the six cell lines examined, including 
those in which it induced IGF-1R and/or PI3K/AKT activation (Figure 6B). Thus, 
unlike IGF, HGF may be more potent at promoting resistance because it leads to 
activation of both the PI3K/AKT and ERK pathways. Unexpectedly, IGF restored 
PI3K/AKT signaling in PC-9 cells, but these cells still remained highly sensitive to 
EGFR-inhibition after 72 hours (Figure 6A, B). This disconnect between maintenance 
of PI3K/AKT signaling and lack of an effect on cell viability is not due to a brief, 
transient restoration of downstream signaling, as we observed that IGF maintained 
PI3K signaling in PC-9 cells for at least 24 hours in the presence of gefitinib (data not 
shown).  
HGF rescue of PI3K signaling is mediated though GAB1 instead of ERBB3 
MET amplified gefitinib resistant HCC827 GR cells utilize ERBB3 as the 
primary adaptor to activate PI3K/AKT signaling (Engelman et al., 2007b). Although 
HGF treatment was sufficient to rescue AKT phosphorylation in several EGFR-driven 
cell lines in the presence of TKIs, ERBB3 phosphorylation was not restored (Figure 
5D).  This suggests that HGF-induced MET activation utilizes an adaptor other than 
ERBB3 to activate PI3K signaling. To determine which PI3K adaptors were being 
utilized to maintain HGF-mediated PI3K signaling, we immunoprecipitated the p85 
regulatory subunit of PI3K and examined co-precipitating phosphotyrosine proteins 
(Engelman et al., 2005; Engelman et al., 2007b; Guix et al., 2008). As expected, 
treatment with a TKI disrupted the association of ERBB3 (and other phosphotyrosine 
proteins) with p85, and the addition of HGF did not restore the interaction (Figure 
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8A). However, we observed that HGF potently induced the association between p85 
and Grb2 associated binder 1 (GAB1), which runs as a broad, highly tyrosine-
phophorylated band at approximately 110kDa. 
To more directly assess if GAB1 mediates HGF-mediated activation of 
PI3K/AKT signaling and cell viability, we used small interfering RNA (siRNA) to 
knockdown GAB1 expression in the HCC827 cells.  Knockdown of GAB1 reduced 
HGF-mediated rescue of PI3K/AKT signaling (Figure 8B), and inhibited the ability of 
27
HGF to rescue HCC827 cells from gefitinib induced cell death (Figure 8C). Of note, 
although the addition of HGF leads to substantial loss of GAB1 protein (Figure 8B), 
the amount of tyrosine phosphorylated GAB1 is dramatically increased (data not 
shown, see Turke et al, Cancer Cell 2010, Supplemental Figure 3), and this 
facilitates the efficient coupling to PI3K (Figure 8A). Thus, activation of HGF/MET 
signaling can lead to gefitinib resistance in EGFR mutant cancers by activating 
PI3K/AKT signaling through two different adaptors: ERBB3 when MET is activated 
by genomic amplification or GAB1 when MET is activated by HGF. 
Analyses of tumors with acquired resistance to gefitinib/erlotinib reveal increased 
HGF expression in resistant cancers 
 To determine the clinical implications of these in vitro and in vivo
observations, we examined tumor specimens from gefitinib or erlotinib treated EGFR
mutant NSCLC patients (Table 1). All patients had a clinical partial tumor response to 
gefitinib or erlotinib treatment and subsequently developed clinical drug resistance. 
We evaluated 27 patients, 16 with paired pre and post geftinib/erlotinib treatment 
specimens and 11 with drug resistance specimens alone. All specimens, when 
feasible, were evaluated for MET amplification, HGF expression by 
immunohistochemistry (IHC), and presence of EGFR T790M (Table 1, Figure 9). We 
observed EGFR T790M in 55 % (15/27) and MET amplification in 4/27 (15%) of 
resistant tumor specimens. In patients with paired tumor specimens, HGF expression 
was higher in the drug resistant specimens compared to pre-treatment specimens (p 
= 0.025; Wilcoxon signed-rank test). In patients with drug resistant specimens alone, 
HGF expression was similar to that of drug resistant specimens in patients with  
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paired tumor specimens. Together these findings support our in vitro and in vivo
studies on HGF mediating resistance to EGFR TKIs.  
29
2.5 Discussion 
EGFR targeted therapies have shown promising results in cancers with 
EGFR activating mutations.  However, resistance frequently occurs within 12 
months. Previously, resistance mechanisms have focused on RTK mutations or 
amplifications, including the T790M mutation in EGFR kinase and amplification of the 
MET receptor (Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; 
Pao et al., 2005).  Recent studies highlight examples of ligand over expression, or 
de-repression, leading to activation of parallel signaling pathways (Guix et al., 2008; 
Yano et al., 2008) and resistance to targeted therapies. 
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In this study, we show that HGF can independently rescue bothPI3K/AKT and 
ERK signaling in the presence of gefitinib and lead to drug resistance both in vitro
and in vivo. Interestingly, cells that use HGF to maintain MET signaling utilize GAB1 
to activate PI3K and are slightly less sensitive to combined MET and EGFR inhibition 
compared to MET amplified gefitinib resistant cells that maintain PI3K signaling 
through ERBB3.  Thus, it may be useful to investigate the signaling advantages and 
disadvantages conferred by GAB1 versus ERBB3 as activators of PI3K. Of note, we 
also observed that although HGF restores the association of GAB1 with p85 in BT-
474 cells (Figure 8A), this is insufficient to restore PI3K/AKT signaling or cell viability 
in the presence of lapatinib.
 Higher levels HGF can be detected in tumor specimens from NSCLC patients 
that are clinically resistant to gefitinib or erlotinib compared to pre-treatment tumor 
specimens (Table 1, Figure 9). Notably in some patients without evidence of EGFR
T790M or MET amplification, HGF expression is greater in the resistant specimen 
(patients 1 (Figure 9B) and 14) than in the pre-treatment specimen, supporting a role 
for HGF alone in promoting drug resistance. This is consistent with prior 
observations (Yano et al., 2008).  Ligand mediated drug resistance is unique to HGF 
as IGF does not rescue TKI-induced cell death in the majority of cell lines tested. 
Surprisingly, IGF did not restore P13K/AKT signaling in most EGFR mutant cancers, 
despite substantial levels of IGF-1R expression and tyrosine phosphorylation. 
Furthermore, unlike HGF, IGF did not restore ERK signaling even in cell lines in 
which it restored PI3K/AKT signaling in the presence of a TKI. These signaling 
differences between HGF and IGF may underlie the lack of drug resistance induced 
by IGF.  
 Our current findings provide insight into future therapeutic strategies for the 
treatment of EGFR mutant NSCLC.  Although MET amplification has been detected 
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in up to 20% of EGFR mutant patients that develop acquired resistance to gefitinib or 
erlotinib, activation of MET signaling (by both amplification and mediated by HGF) 
may in fact account for a larger fraction of gefitinib/erlotinib resistant tumors. It is 
tempting to speculate that HGF production by the stroma may also partially explain 
why clinical resistance emerges discordantly in some tissues like the liver, bone and 
brain, while pulmonary disease continues to respond to erlotinib treatment (Dr. 
Jeffrey Engelman, personal observation).   These results highlight a new cohort of 
patients, beyond those with MET amplification, who may benefit from combined 
HGF/MET and EGFR targeted therapies.
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Chapter 3- Preexistence and clonal selection of MET amplified cells2
3.1 Abstract 
The therapeutic success of EGFR tyrosine kinase inhibitors (TKIs) in EGFR
mutant lung cancers is limited by the development of drug resistance, mediated by 
MET amplification in a subset of patients.  Our group has previously shown that the 
EGFR-driven cell line, HCC827, develops MET amplification as a resistance 
mechanism to the EGFR inhibitor gefitinib (Engelman et al., 2007b).  In this study, 
my colleagues and I developed a second resistance model using the HCC827 cell 
line and showed that these cells also develop MET amplification in response to 
treatment with an irreversible EGFR inhibitor.  Using high-throughput FISH analyses 
we determined that parental HCC827 cells harbor a small (<1%) preexisting 
population of MET amplified cells, making them uniquely poised to develop MET
amplification as a resistance mechanism.  In non-small cell lung cancer (NSCLC) 
patient samples, detection of pre-existing MET amplified cells before treatment 
accurately predicted the development of MET amplification as a resistance 
mechanism. Surprisingly, expression of the MET ligand, HGF, dramatically 
accelerated the development of MET amplification both in vitro and in vivo.  These 
findings provide insight into the origins of drug resistance in EGFR mutant cancers, 
and highlight the potential to prospectively identify treatment naïve EGFR mutant 
lung cancer patients who will benefit from initial combination therapy. 
3.2 Introduction 
Non-small cell lung cancers (NSCLCs) with EGFR activating mutations have 
been shown to respond to EGFR targeted therapies including the kinase inhibitors 
                                                
2 Excerpts and figures from this chapter were published in Turke, et al., Cancer Cell, January 
2010.
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gefitinib and erlotinib (Mok 2008, Sequist 2008).  However, despite dramatic initial 
responses, patients often develop resistance within 12 months (Engelman and 
Settleman, 2008; Sharma et al., 2007).  Thus far, two mechanisms of acquired 
resistance have been validated in patients.  The first involves a secondary mutation 
in EGFR itself, including the EGFR T790M “gatekeeper” mutation, which is observed 
in 50% of resistance cases (Balak et al., 2006; Kobayashi et al., 2005; Pao et al., 
2005). Second, activation of MET signaling via amplification of the MET receptor 
occurs in at least 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; 
Engelman et al., 2007b; Kosaka et al., 2006).  In the previous chapter, we described 
a novel mechanism of resistance in which MET signaling is activated by the HGF 
ligand, leading to maintenance of PI3K/AKT signaling and cell viability in the 
presence of an EGFR inhibitor (Turke et al., 2010). 
 Strategies for overcoming acquired resistance to gefitinib are now undergoing 
clinical evaluation. In preclinical studies, the T790M mutant EGFR can be effectively 
inhibited by second-generation, irreversible EGFR inhibitors (Engelman et al., 2007a; 
Kobayashi et al., 2005; Riely, 2008). Indeed, there are now clinical trials assessing 
both irreversible EGFR inhibitors and a combination of MET and EGFR inhibitors in 
patients with acquired resistance to gefitinib/erlotinib. Further, clinical activity of the 
irreversible EGFR inhibitor, PF00299804, has been observed in NSCLC patients that 
have developed acquired resistance to gefitinib/erlotinib (Janne et al., 2008). As an 
alternative strategy, to delay or avoid the emergence of resistance, there is 
increased enthusiasm to utilize agents effective against specific resistance 
mechanisms as initial systemic therapies. However, methods to determine which 
resistance mechanism will develop, diagnostic tests to detect these changes, and 
factors influencing the kinetics of resistance are still largely unknown. 
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  In this study, we modeled in vitro resistance to PF00299804 in the TKI 
sensitive EGFR mutant NSCLC cell line HCC827 (Engelman et al., 2007b; Ogino et 
al., 2007).  We also examined HCC827 cells exposed transiently to HGF ligand in 
the presence of an EGFR inhibitor. Surprisingly, the results from both of these 
avenues of investigation led us to determine that MET amplification pre-exists in a 
subpopulation of cells prior to treatment with a TKI, and that HGF dramatically 
accelerates the selection of these cells. The findings from these analyses suggest 
that assessment of treatment naïve cancers can inform more effective clinical 
therapeutic strategies for EGFR mutant lung cancer patients.  
3.3 Materials and Methods 
Cell culture reagents, viability studies and Western analyses  
 HCC827 GR (del E746_A750/MET amplified) cells were maintained in RPMI 
1640 (Cellgro; Mediatech Inc., Herndon, CA) supplemented with 5% FBS and have 
been described previously (Engelman et al., 2007b).  H3255 cells were maintained in 
ACL-4 media (Invitrogen, Carlsbad, CA) supplemented with 5% FBS. All growth 
medium was supplemented with 100 units/mL penicillin, 100 units/mL streptomycin, 
and 2 mM glutamine.  Cell lines and growth conditions for HCC827 and PC-9 cells, 
as well as EGFR and MET inhibitors are described in Chapter 2 Materials and 
Methods. Cell viability was assessed 72 hours following drug exposure by Syto60 
staining (Invitrogen) as described in Chapter 2. Cells were lysed in an NP-40 
containing lysis buffer, separated by SDS/PAGE electrophoresis and transferred to 
PVDF membranes.  Immunoblotting was performed according to the antibody 
manufacturer’s recommendations.  Antibody binding was detected using enhanced 
chemiluminescence (PerkinElmer, Waltham, MA) and antibodies are described in 
detail in Chapter 2. 
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Generation of in vitro drug resistant HCC827 cells 
 To generate a resistant cell line, HCC827 cells were exposed to increasing 
concentrations of PF00299804 similar to our previously described methods 
(Engelman et al., 2006b; Engelman et al., 2007b). PF00299804 concentrations were 
increased stepwise from 1 nM to 1 µM when the cells resumed growth kinetics 
similar to untreated parental cells. To confirm the emergence of a resistant clone, 
MTS assays were performed following growth at each concentration.   
Xenograft Studies
 HCC827 PFR6 xenograft studies were performed in accordance with the 
standards of the Institutional Animal Care and Use Committee (IACUC) under a 
protocol approved by the Animal Care and Use Committee of Massachusetts 
General Hospital as described in Chapter 2 Materials and Methods. PF2341066 was 
dissolved in sterile water and administered at 25mg/kg/day.  PF00299804 was 
dissolved in a 0.05N lactate buffer and administered at 10 mg/kg/day. 
SNP analyses
 SNP analyses to evaluate genome wide copy number changes were 
performed as previously described (Engelman et al., 2007b). Comparison of gene 
copy number between HCC827 and the PFR clones was performed using dChip 
software according to previously established methods (Engelman et al., 2007b; Zhao 
and Vogt, 2008).  SNP data is available from the ncbi gene expression omnibus 
database (accession number: GSE18797). 
EGFR and MET genomic analyses 
36
 The EGFR tyrosine kinase domain (exons 18-21) from the HCC827 PFR 
clones were examined for genetic alterations using a modification of previously 
described sensitive gene scanning methods (Engelman et al., 2006b; Janne et al., 
2006). The PCR primers and conditions are available upon request. The relative 
copy number for MET was determined using quantitative real time PCR using a 
PRISM 7500 sequence detection kit (Applied Biosystems) and a QuantiTect SYBR 
Green PCR Kit (Qiagen, Inc., Valencia, CA) and as previously described (Engelman 
et al., 2007b). 
FISH probes and hybridization 
 Bacterial artificial chromosome (BAC) clones CTD-2257H21 (EGFR (7p11.2)) 
and RP11-95I20 (MET (7q31.2)) were purchased from Children’s Hospital Oakland 
Research Institute (CHORI; Oakland, CA).  DNA was extracted using a Qiagen kit 
(Valencia, CA) and labeled with Spectrum Green- or Spectrum Orange-conjugated 
dUTP by nick translation (Vysis/Abbott Molecular, Des Plaines, IL). The CEP7 probe 
(Vysis/Abbott Molecular, Des Plaines, Il) was used according to manufacturer’s 
instructions. Chromosomal mapping and hybridization efficiency for each probe set 
were verified in normal metaphase spreads (data not shown). Three color FISH 
assays were performed as previously described (Engelman et al., 2007b).   
High throughput fluorescence in situ hybridization 
 A Bioview work station with DuetTM software (Bioview Ltd, Rehovot, Israel) was 
used to screen for rare MET amplified cells. Automatic scans were performed according 
to manufacturer’s suggested guidelines after setting classification criteria for each FISH 
probe.  Images were captured and classified in an automated fashion and manually 
reviewed to ensure accuracy. Any unclassified images were manually reviewed and 
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scored. Any cells that could not be scored were excluded from the analysis. Paraffin 
embedded specimens derived from NSCLC patients or from xenografts were manually 
scanned for evidence of MET amplification. 
FACS analysis for GFP positive cells 
 Cells were harvested, resuspended in 0.5% FBS in phosphate buffered saline, 
and stained with 1µg/mL Propidium Iodide (PI) Staining Solution (BD Biosciences, 
San Jose, CA). Cells were analyzed on a FACSAria flow cytometer (BD Biosciences, 
San Jose, CA) equipped with a 30mW Argon air-cooled laser and signals were 
detected through a 530/30 bandpass filter for GFP and 575/26 bandpass for PI.  
NSCLC Patients 
 Tumor specimens from gefitinib or erlotinib treated patients analyzed for MET 
copy number, EGFR mutational status and HGF expression level are described in 
detail in Chapter 2 Material and Methods. 
3.4 Results 
MET amplification causes resistance to the irreversible EGFR inhibitor PF00299804 
by activating ERBB3 signaling.  
We generated in vitro resistant clones of HCC827 cells to the irreversible 
pan-ERBB kinase inhibitor, PF00299804, using previously described methods 
(Engelman et al., 2006b; Engelman et al., 2007b). HCC827 cells were exposed to 
increasing concentrations of PF00299804, starting with 1nM, until they were able to 
proliferate freely in 1M PF00299804, which occurred after 6 months of drug 
selection. This concentration was chosen because it is ~1000 fold greater than the  
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IC50 for growth inhibition of HCC827 cells and approximately 5 times greater than the 
serum concentration of PF00299804 observed in NSCLC patients in the phase I 
clinical trial (Janne et al., 2008; Schellens et al., 2007). Five independent clones 
were isolated and expanded for further studies. All five HCC827 PF00299804 
Resistant (PFR) clones were resistant to PF00299804 in vitro (Figure 10A and data 
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not shown). No secondary EGFR mutations (e.g. T790M) were detected in any of the 
clones (data not shown).  
We next examined the effects of PF00299804 on EGFR, ERBB3, AKT and 
ERK phosphorylation in the HCC827 PFR clones. Unlike in parental HCC827 cells, 
ERBB3 activation as well as downstream PI3K/AKT and ERK signaling is maintained 
in the presence of PF00299804 in HCC827 PFR cells (Figure 10B). We also 
observed increased total MET protein in the HCC827 PFR cells, and combined MET 
and EGFR inhibition down-regulated ERBB3, AKT and ERK phosphorylation as well 
as the modest EGFR phosphorylation that was maintained in the presence of 
PF00299804 alone (Figure 10B). This behavior following treatment with PF00299804 
alone or in combination with a MET inhibitor is similar to that observed in gefitinib 
resistant HCC827 cells (HCC827 GR cells), which were generated in an analogous 
manner and contained a focal amplification in chromosome 7 harboring the MET 
oncogene (Engelman et al., 2007b). 
Given the similarities in the HCC827 PFR and GR cells following treatment 
with either PF00299804 or gefitinib, respectively, we determined whether the 
addition of a MET inhibitor would overcome resistance to PF00299804. We used 
both a tool compound PHA-665,752 and the MET inhibitor PF2341066 currently 
undergoing clinical development (Figure 10C, upper and data not shown) (Zou et al., 
2007). The combination of PF00299804 and a MET inhibitor effectively inhibited the 
growth of HCC827 PFR cells while neither agent alone led to growth inhibition 
(Figure 10C, upper and data not shown).  In addition, the combination of gefitinib and 
PF2341066 also effectively inhibited the growth of HCC827 PFR cells (Figure 10C, 
lower). These findings further suggest that the resistance mechanism in the HCC827 
PFR cells is not unique or dependent on the differences between reversible 
(gefitinib) or irreversible (PF00299804) EGFR inhibitors but rather due solely to MET
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amplification. We also evaluated the effects of the irreversible EGFR inhibitor 
PF00299804 and the MET inhibitor PF2341066 in an HCC827 PFR xenograft model. 
Treatment with PF00299804 alone was modestly more effective than treatment with 
PF2341066 alone, but the tumors demonstrated resistance to PF00299804. 
However, combined MET and EGFR inhibition completely inhibited tumor growth and 
produced complete responses (p<0.0001; Figure 10D).  In fact, the combination 
treatment was discontinued after 56 days (Figure 10D; arrow) and no tumor re-
growth has been observed to date in any of the xenografts (after more than 35 
weeks off therapy) (Figure 10D), suggesting that the mice have been cured.  
We next determined whether the increase in MET protein expression was 
due to MET amplification in the HCC827 PFR cells (Figure 11A). All of the PFR 
clones contained at least a four fold amplification of MET, similar to the amplification 
previously observed in the gefitinib resistant HCC827 (HCC827 GR) cells 
((Engelman et al., 2007b) and Figure 11A). All of the PFR clones also had higher 
levels of MET protein expression (Figure 11B).  Genome-wide SNP analysis 
revealed that the only area of significant copy number gain in HCC827 PFR cells is 
on distal chromosome 7, similar to that observed in HCC827 GR cells, and contains 
the MET oncogene (Figure 11C, D).  Furthermore, HCC827 PFR and GR cells share 
single copy losses of 4p, 5q, 14p, 14q and 19p, but only HCC827 PFR cells have a 
single copy loss of 16q. Intriguingly, further examination of the region of MET
amplification on distal chromosome 7 in both set of clones showed that, although the 
copy number changes within the amplicons are not identical in the HCC827 GR and 
PFR cells, the size and the proximal borders of the amplicons are very similar 
(Figure 11D). Together these findings, along with the multiple shared regions of 
single copy genomic loss between the HCC827 PFR and GR cells, suggest that the 
resistant clones may have arisen from a common origin.  
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Transient HGF exposure leads to the development of MET amplification and stable 
ligand-independent gefitinib resistance in HCC827-50GR cells 
As described in the previous chapter, HGF ligand potently activates 
PI3K/AKT and MEK/ERK signaling in EGFR driven cell lines and causes resistance 
to gefitinib.  However, because HGF-induced resistance to EGFR TKIs appears 
intimately linked to ligand-induced activation of downstream signaling, we 
hypothesized that long-term resistance would require continuous exposure to HGF. 
We observed that by replenishing cells with HGF in combination with the EGFR TKI 
every 3 days, cells continue to be highly resistant indefinitely (data not shown). Thus, 
we treated each cell line with HGF in the presence of an EGFR inhibitor for 14 days, 
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and then removed HGF, but maintained the cells in the EGFR TKI.  Surprisingly, 
HCC827 cells treated transiently with HGF remained permanently resistant to 
gefitinib after HGF withdrawal (Figure 12A, B).   
These stably resistant cells were termed HCC827-50GR (50ng HGF Gefitinib 
Resistant) cells (Figure 12A). In contrast, HCC827 cells that are not pretreated with 
HGF, develop gefitinib resistance only after 6 months of gradually increasing 
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concentrations of drug exposure (Engelman et al., 2007b). In addition, when 
HCC827-50GR cells were grown in media alone (without gefitinib) for eight weeks, 
these cells (HCC827-50GR (8wksR5)) maintained their resistance (Figure 12D). 
Treatment with HGF alone (without gefitinib) for 14 days did not yield stably resistant 
cells (Figure 13). Thus, lasting resistance conferred by transient HGF requires the 
selective pressure of gefitinib during ligand exposure. 
Stably resistant HCC827-50GR cells maintained PI3K/AKT, mTORC1 and 
ERK activation in the presence of gefitinib. Surprisingly, ERBB3 also remained 
phosphorylated in HCC827-50GR cells treated with gefitinib (Figure 12E), which 
suggests that although initial HGF-mediated resistance mechanisms utilized GAB1 to 
activate PI3K/AKT signaling, the ligand-independent HCC827-50GR cells utilize 
ERBB3 to activate PI3K/AKT signaling. This observation suggests that short-term 
exposure to HGF may lead HCC827 cells to develop or select the same mechanism 
of stable resistance, through activation of ERBB3/PI3K signaling, as was observed in 
MET amplified HCC827 GR cells (Engelman et al., 2007b). Unlike the HCC827 cells, 
several other EGFR-driven cancer cell lines that were made resistant to EGFR TKIs 
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by HGF treatment did not maintain stable ligand-independent resistance after the 
withdrawal of HGF (data not shown, see Turke at al., Cancer Cell 2010, 
Supplemental Figure 4). These findings suggest that HCC827 cells are uniquely 
poised to develop stable ligand-independent resistance. 
Stably-resistant HCC827-50GR cells had increased total MET protein levels 
compared to parental cells and maintained MET phosphorylation in the presence of 
gefitinib (Figure 12E), mimicking MET amplified HCC827 GR cells. Therefore, we 
examined MET copy number using fluorescent in situ hybridization (FISH), and found 
significant MET copy number gains in HCC827-50GR cells compared to parental 
cells (Figure 12C). Quantitative PCR demonstrated a three to four fold amplification 
of MET, similar to the HCC827 GR and PFR cells (data not shown). These results 
suggest that MET amplification may be driving ERBB3/PI3K/AKT signaling and 
gefitinib resistance in HCC827-50GR cells. 
To examine this hypothesis, we exposed HCC827-50GR cells to PHA-
665,752 alone or in combination with gefitinib. Only the combination of gefitinib and 
PHA-665,752 resulted in a substantial reduction in the number of viable cells (Figure 
12D, upper). In addition, the HCC827-50GR (8wks R5) cells (grown in media without 
gefitinib for eight weeks) also remained sensitive only to the combination of MET and 
EGFR inhibition (Figure 12D, lower). Further, treatment with gefitinib in combination 
with PHA-665,752 completely blocked ERBB3 phosphorylation as well as 
downstream PI3K/AKT, mTORC1 and ERK signaling in HCC827-50GR and 
HCC827-50GR(8wks R5) cells (Figure 12E). Taken together, these results suggest 
that MET inhibition restores EGFR dependence and gefitinib sensitivity in HCC827-
50GR cells. 
These results led us to examine tissue sections from HCC827-HGF xenograft 
models treated with gefitinib (Figure 7C). Of three tumors that developed gefitinib 
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resistance, one exhibited significant MET amplification (Figure 14A). Thus, MET
amplification is also facilitated by HGF in vivo. 
HCC827 cells harbor a small subpopulation of preexisting MET amplified cells and 
HGF dramatically accelerates the selection of these cells 
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Because HCC827 GR, PFR and 50GR cells all eventually develop focal MET
amplification as a resistance mechanism, we hypothesized that parental HCC827 
cells may harbor a pre-existing MET amplified clone. We analyzed 4237 individual 
HCC827 cell nuclei using high-throughput fluorescence in situ hybridization (FISH) 
(see Materials and Methods) and identified 6 cells (0.14%; 6/4237) that harbored 
significant MET copy number gains (Figure 14B, C). These results were confirmed in 
an independent experiment using a second gefitinib sensitive parental HCC827 cell 
line (HCC827 N1; Figure 14C). We also generated two subclones derived from 
single cells from the gefitinib sensitive parental HCC827 cell line (HCC827 C1 and 
C2). Both subclones were sensitive to gefitinib in vitro (data not shown), and each 
also contained a low frequency population of MET amplified cells (Figure 14C). We 
further examined the gefitinib sensitive H3255 and PC-9 cells using FISH. Gefitinib 
resistant clones of both H3255 and PC-9 have been isolated and reported to contain 
the EGFR secondary resistance mutation T790M but not MET amplification 
(Engelman et al., 2006b; Ogino et al., 2007). We did not detect a subpopulation of 
MET amplified cells in the H3255 or the PC-9 cells (Figure 14C).  
We hypothesized that the mechanism by which transient treatment with HGF 
and gefitinib leads to the generation of MET amplified HCC827-50GR cells is by 
selecting out this small population of preexisting MET amplified cells from the 
parental HCC827 cell population. To test this hypothesis, we spiked unlabeled 
HCC827 parental cells with 0.1% of either GFP labeled HCC827 cells or GFP 
labeled MET amplified HCC827 GR6 cells. We treated these two populations with 
either media alone (no selection) or with gefitinib in combination with HGF. Media 
was changed and fresh HGF was added every 72 hours, and cells were collected 
after 19 days for FACS to quantify the percent of cells with GFP expression. As 
expected, there was no significant change in the percentage of GFP labeled 
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HCC827 cells at the end of 19 days. However, the percentage of GFP labeled MET
amplified HCC827 GR6 cells increased over 300 fold to almost 33% in just over two 
weeks (Figure 14D). Taken together, these results suggest that HGF exposure in the 
presence of an EGFR inhibitor leads to the rapid selection of a pre-existing MET
amplified clone in the HCC827 cells (Figure 15).  
Analyses of tumors with acquired resistance to gefitinib/erlotinib reveal evidence of 
pre-treatment MET amplification in resistant cancers. 
 To determine the clinical implications of these observations, we further 
examined tumor specimens from the panel of paired pre and post treatment samples 
from NSCLC patients previously described in chapter two (Table 1). Each of these 
patients had a clinical partial tumor response to gefitinib or erlotinib treatment and 
subsequently developed clinical drug resistance.   We observed EGFR T790M in 
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15/27 (55%) and MET amplification in 4/27 (15%) of resistant tumor specimens.  We 
evaluated each of the16 pre-treatment specimens for evidence of MET amplification. 
In all 4 patients with MET amplification in the drug resistant specimens, we observed 
rare (<1%) tumor cells with MET amplification in the corresponding pre-treatment 
specimens (Table 1, Figure 16). In contrast, of 8 cases that had resistant cancers 
without MET amplification, we observed rare MET amplified tumor cells in only 1 of 
the corresponding pre-treatment tumor specimens. These findings are consistent 
with cell line data (Figure 14B, C) where we observed evidence of pre-existing MET
amplification only in the cell line that subsequently develops MET amplification as its 
resistance mechanism. 
3.5 Discussion 
Kinase inhibitors have emerged as effective clinical therapies for cancers that 
exhibit oncogene addiction to a particular kinase (Demetri et al., 2002; Druker et al., 
2001; Inoue et al., 2006; Mok et al., 2008; Sequist et al., 2008). However, the clinical 
success of kinase inhibitor therapies is uniformly limited by the development of drug 
resistance. To date, resistance mechanisms have predominately involved secondary 
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genomic alterations in the target kinase that alter either the physical (such as steric 
hindrance) or biochemical (change in ATP affinity) properties of the receptor and 
result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 2008). We 
have previously described MET amplification as a mechanism of gefitinib resistance 
in EGFR mutant cancers (Engelman et al., 2007b), leading to persistent activation of 
both PI3K/AKT and ERK signaling in the presence of the EGFR TKI (Engelman et 
al., 2007b).  
A critical question for all resistance mechanisms to kinase inhibitors is 
whether they occur as a result of treatment or whether they preexist prior to 
treatment and are selected out during the course of therapy. At least some imatinib 
resistant CML clones are thought to be present at low levels prior to treatment and 
undergo clonal selection during imatinib exposure (Hofmann et al., 2003; Roche-
Lestienne et al., 2003; Roche-Lestienne et al., 2002; Shah et al., 2002). Similarly, 
EGFR T790M can be detected at low levels in EGFR mutant NSCLC patients prior to 
gefitinib or erlotinib treatment (Maheswaran et al., 2008). Our current findings 
provide support that this may also be the case for MET amplification both in HCC827 
cells (Figure 15) and in NSCLC patients that subsequently develop MET
amplification at the time of clinical gefitinib or erlotinib resistance (Table 1). The 
identification of a drug resistance mechanism from a pre-treatment tumor specimen 
provides the opportunity to specifically target that resistance mechanism prior to its 
emergence. This approach is clinically appealing as combined treatment with an 
EGFR and MET inhibitor, specifically in patients with evidence of MET amplification 
at baseline, may lead to a longer time to progression than is currently observed with 
gefitinib or erlotinib alone (Asahina et al., 2006; Inoue et al., 2006; Mok et al., 2008; 
Paz-Ares et al., 2006; Sequist et al., 2008; Tamura et al., 2008). In fact, combined 
EGFR and MET inhibition in HCC827 cells extinguishes the emergence of MET
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amplified drug resistant clones (data not shown). However, it will be critical to learn 
whether upfront treatment with combination therapy is tolerable (toxicity) and/or will 
provide more clinical benefit than treatment at the time of relapse. 
Intriguingly, HCC827 cells appear to be pre-disposed to the development of 
low level MET amplification as subclones of cells expanded from single cell clones 
derived from parental HCC827 cells (HCC827 N1 and N2) also are found to contain 
low levels of MET amplification (Figure 14C).  MET is located at a fragile site in 
chromosome 7, which facilitates its amplification, and subsequently a selection for 
clones harboring MET amplification can occur under drug pressure (Hellman et al., 
2002). Why this occurs only in the HCC827 cells and a subset of lung cancers, and 
not in other EGFR mutant cell lines and cancers, is currently unknown. Collectively, 
these studies suggest, but do not prove that the specific mechanisms of resistance 
that will develop as a result of drug exposure may be pre-determined and occur as a 
result of drug selection. Understanding why some EGFR mutant cancers are pre-
disposed to develop MET amplification will help further refine the clinical 
development of EGFR and MET inhibitor combinations.  
In this study, we demonstrate that in addition to its ability to activate 
downstream signaling pathways and mediate short-term resistance in multiple 
EGFR-driven cell line models, HGF also accelerates the emergence of MET
amplification in HCC827 cells both in vitro and in vivo. Intriguingly, this process 
requires concomitant EGFR inhibition, as HGF exposure alone does not lead to 
emergence of MET amplified clones. It is possible that in the presence of EGFR 
inhibition, HGF provides a unique proliferative advantage to a subset of cells with 
high MET expression (those with amplification) thus facilitating their rapid clonal 
expansion. Activation of MET signaling is a unique resistance mechanism to kinase 
inhibitors as it can occur through multiple independent mechanisms, amplification 
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and/or ligand mediated, and when combined can lead to rapid evolution of drug 
resistance.  
 Our current findings suggest further therapeutic strategies for EGFR mutant 
NSCLC.  First, this study implies that the therapeutic combination of an irreversible 
EGFR inhibitor (effective against EGFR T790M) and a MET inhibitor is an attractive 
treatment combination for a significant portion of gefitinib/erlotinib resistant EGFR
mutant NSCLC patients. In addition, these findings highlight the potential to 
prospectively identify treatment naïve EGFR mutant lung cancer patients who are 
likely to develop MET amplification and may benefit from initial combination therapy 
with a MET inhibitor.  Finally, our results suggest that in patients with high levels of 
HGF expression, the kinetics of selection of preexisting MET amplified cells and the 
development of resistance to single agent EGFR inhibitors will be accelerated.  
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Chapter 4- MEK feedback activation of PI3K/AKT signaling3  
4.1 Abstract 
 The PI3K/AKT and RAF/MEK/ERK signaling pathways are critically activated 
in a wide range of human cancers.  In many cases, inhibition of both pathways is 
necessary to block proliferation and induce cell death and tumor shrinkage.  Several 
feedback systems have been described in which inhibition of one intracellular 
pathway leads to activation of a parallel signaling pathway, thereby decreasing the 
effectiveness of single-agent targeted therapies.  In this study we describe a 
feedback mechanism in which MEK inhibition leads to activation of PI3K/AKT 
signaling in EGFR and HER2 driven cancers.  We find that MEK inhibitor-induced 
activation of PI3K/AKT results from hyperactivation of ERBB3.  This is caused by 
loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane (JM) 
domains of EGFR and HER2.  Mutation of this amino acid leads to increased ERBB 
receptor activation and up-regulation of ERBB3/PI3K/AKT signaling, that is no longer 
responsive to MEK inhibition.  These results further characterize the important 
feedback networks regulating central oncogenic pathways in human cancer and 
support the use of combination therapies in the clinic. 
4.2 Introduction 
 The phosphatidylinositol 3-kinase (PI3K), RAF/MEK/ERK mitogen-activated 
protein kinase (MAPK), and mammalian target of rapamycin complex 1 (mTORC1) 
signaling pathways transmit signals from membrane bound receptor tyrosine kinases 
(RTKs) to multiple downstream effector networks regulating cell growth, metabolism, 
                                                
3 Excerpts and figures from this chapter are in preparation for submission (Turke et al. MEK 
inhibition relieves a negative feedback on ERBB receptors activating PI3K/AKT signaling. 
2011 (in preparation)).
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survival, and proliferation (Engelman, 2009; Guertin and Sabatini, 2007; Montagut 
and Settleman, 2009).  Numerous feedback systems regulating these central 
oncogenic pathways have been described, and these feedbacks can impact the 
sensitivity of cancers to specific kinase inhibitors.  For example, inhibition of 
mTORC1 relieves proteasomal degradation of IRS-1 leading to feedback up-
regulation of IRS-1/PI3K/AKT signaling, reducing the efficacy of mTORC1 inhibitors 
as single agents and prompting the use of combination therapies (Carracedo et al., 
2008; O'Reilly et al., 2006).  PI3K and AKT inhibitors have been shown to relieve a 
negative feedback on ERBB receptors and other RTKs through de-repression of 
forkhead transcription factors, leading to increased transcription of these receptors.  
Increased RTK expression correlates with partial re-activation of PI3K/AKT signaling, 
MEK/ERK signaling, and other downstream pathways, potentially limiting the utility of 
PI3K inhibitors as single agents (Chakrabarty et al., 2011; Chandarlapaty et al., 
2011; Serra et al., 2011). Similarly, we and others have shown that MEK inhibition 
leads to increased AKT activation, often resulting in reduced efficacy of MEK 
inhibitors as single agents (Faber et al., 2009; Hoeflich et al., 2009; Mirzoeva et al., 
2009).  However, the mechanism by which MEK inhibition leads to increased AKT 
signaling has not yet been resolved.   
Targeted therapies such as the EGFR inhibitors gefintinib and erlotinib are 
extremely effective when cells are “addicted” to EGFR.  Inhibition of the driving RTK 
leads to down-regulation of critical growth and survival signaling pathways, 
especially PI3K/AKT and MEK/ERK (Engelman and Settleman, 2008; Faber et al., 
2009; Ono et al., 2004). We recently determined that treatment with a combination of 
a MEK inhibitor and a PI3K inhibitor led to significant apoptosis in EGFR-driven 
cancers, similar to that induced by an EGFR TKI, whereas treatment with either 
pathway inhibitor alone was not sufficient to induce marked cell death (Faber et al., 
54
2009).  In those studies, we observed that treatment with a single-agent MEK 
inhibitor led to increased activation of AKT phosphorylation. Currently, there are 
multiple MEK and BRAF inhibitors, including the highly selective allosteric MEK1/2 
inhibitor, AZD6244 (Yeh et al., 2007), being developed as cancer treatments. 
However, the feedbacks induced by MEK inhibitors that may ultimately impact their 
utility are poorly understood.  
In cancers that are addicted to receptor tyrosine kinases, such as EGFR
mutant lung cancers and HER2 amplified breast cancers, receptor dimerization leads 
to tyrosine phosphorylation and recruitment of adaptor proteins to the cell 
membrane, which in turn lead to activation of downstream effectors including 
PI3K/AKT and RAF/MEK/ERK signaling pathways.  The ERBB3 receptor is a kinase 
dead member of the ERBB family that commonly serves as a scaffold in EGFR and 
HER2 driven cancers. ERBB3 directly binds to PI3K when it is tyrosine 
phosphorylated at YXXM motifs by other RTKs.  Class I phosphoinositide 3-kinase 
(PI3K) is a heterodimer composed of a p110 catalytic subunit and a p85 regulatory 
subunit.  In un-stimulated cells, PI3K exists in the cytoplasm in an inactive 
conformation.  However, when receptors or adaptor proteins become activated, the 
two p85 src homology 2 (SH2) domains bind to phosphorylated tyrosine residues in 
YXXM motifs.  As a result, PI3K is recruited to the cell membrane and p110 is 
released from p85 inhibition, allowing for the phosphorylation of the membrane lipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) to produce phosphatidylinositol 3,4,5-
trisphosphate (PIP3).  This leads to the recruitment and activation of several 
downstream signaling effectors including AKT.  
 In this study, we examine the molecular mechanism by which MEK inhibition 
leads to increased PI3K/AKT and RAF/MEK signaling. We provide evidence 
suggesting that this feedback activation occurs via ERBB3 through loss of an 
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inhibitory ERK-dependent threonine phosphorylation in the conserved JM domains of 
EGFR and HER2, previously found to regulate to EGFR auto-phosphorylation (Red 
Brewer et al., 2009). Elucidation of this mechanism provides a greater understanding 
of the feedback systems regulating these key pathways that drive human cancers, 
and supports the argument in favor of combining MEK inhibitors with ERBB 
inhibitors, or PI3K inhibitors, in the clinic. 
4.3 Materials and Methods 
Cell culture and reagents 
 The EGFR mutant NSCLC cell lines HCC827 (exon19 del), H4006 (exon19 
del), and H1975 (L858R/T790M) have been previously characterized (Amann et al., 
2005; Engelman et al., 2006b; Engelman et al., 2007b; Turke et al.). The three HER2
amplified cell lines used in this study included BT-474, a breast cancer cell line (a 
kind gift from Dr. Carlos L. Arteaga, Vanderbilt University School of Medicine, 
Nashville, Tennessee), MD-MBA-453 a breast cancer cell line, and NCI-N87 a 
gastric cancer cell line.  The three KRAS mutant colorectal cancer cell lines used in 
this study included SW837, SW1463 and Gp5d cells.  Both MD-MBA-453 and NCI-
N87 cells, and the three KRAS mutant cell lines were provided by the Center for 
Molecular Therapeutics (Massachusetts General Hospital).  HCC827, H4006, 
H1975, NCI-N87, SW1463, SW837, and Gp5d cell lines were maintained in RPMI 
1640 (Cellgro; Mediatech Inc., Herndon, CA) supplemented with 10% FBS.  BT-474 
and MDA-MB-453 cells were maintained in Dulbecco’s Modification of Eagle’s 
Medium (DMEM) (Cellgro; Mediatech Inc., Herndon, CA) supplemented with 10% 
FBS.  CHO-KI cells were purchased from ATCC and maintained in DMEM/F12 
supplemented with 10% FBS.  All growth medium was supplemented with 100 
units/mL penicillin, 100 units/mL streptomycin, and 2 mM glutamine. 
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 AZD6244 (ARRY-142886) was purchased from Selleck Chemicals (Houston, 
TX) and used at 2uM. Rapamycin (Sigma) was used at 50nM.  Gefitinib (American 
Custom Chemical Corporation), lapatinib (LC Laboratories Woburn, MA), the AKT 
inhibitor AKT1/2 (Signa-Gen Laboratories), the PI3K inhibitor GDC-0941 (LC 
Laboratories Woburn, MA), and the IGFR inhibitor NVP-AEW541 (Novartis) were 
each used at 1M. All drugs were dissolved in DMSO for cell culture experiments. 
Antibodies, Western Blotting, and Immunoprecipitiations  
 Cells were lysed in an NP-40 containing lysis buffer, separated by SDS/PAGE 
electrophoresis and transferred to PVDF membranes as previously described 
(Engelman et al., 2007b; Turke et al., 2010).  Immunoblotting was performed 
according to the antibody manufacturer’s recommendations.  Antibody binding was 
detected using enhanced chemiluminescence (PerkinElmer, Waltham, MA).  Anti-
phospho-Akt (Ser 473 and Thr308), anti-phospho-ERBB-3 (Tyr 1289), anti-phospho-
EGFR (Thr 669), anti-phospho-p42/44 MAP kinase (Thr 202 Tyr 204), anti-p42/44 
MAP kinase, anti-phospho-MEK1/2 (Ser 217/221), anti-phospho-C-RAF (Ser 338), 
phospho-GSK3a/B (Ser 21/9), phospho-PRAS40 (Thr 246), phosph-ATP Citrate 
Lyase (Ser 455), anti-PTEN, anti-phospho-S6 ribosomal protein (Ser 335/236), anti-
S6 ribosomal protein, anti-phospho HER2 (Tyr 1211/1222) and anti-phospho-Tyr-100 
antibodies were from Cell Signaling Technology (Beverly, MA).  Anti-ERBB3, anti-
AKT, and anti-EGFR antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). The phospho-specific EGFR (Tyr1068) antibody was from AbCam 
(Cambridge, MA). The anti-HER2 antibody was from Oncogene Research Products 
now Calbiochem (SanDiego, CA). The anti-p85 antibody used for 
immunoprecipitations was from Millipore (Billerica, MA). Anti-NRDP1 antibody was 
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purchased from US Biologicals.  The Quantikine ELISA Kit for quantification of HRG 
in HCC827 cell lysates was purchased from R&D Systems (Minneapolis, MN).   
 For biotin labeling immunoprecipitations, HCC827 cells were washed with 
PBS and labeled for 1 hour at 4 degrees in the presence of 0.5ug/mL Sulfo-NHS-LC-
Biotin (Thermo Scientific) re-suspended in PBS in the presence or absence of 
AZD6244.  Labeling was quenched by washing with 100mM glycine in PBS.  
Following labeling, cells were returned to media and treated for the indicated number 
of hours at 37 degrees before lysis.  Biotin labeled cell surface proteins were 
immunoprecipitated with NeutrAvidin Agarose Resins (Thermo Scientific) overnight, 
separated by SDS page, and immunoblotted to detect the indicated proteins.  
Transferrin receptor was used as an internal loading control. 
PIP2/PIP3 Isolation and Quantification 
 Following treatment, phospholipids were isolated from cells and PIP3 and 
PI(4,5)P2 levels were measured using ELISA kits purchased from Echelon (K-2500s 
and K4500, respectively) according to the manufacturer's instructions.  
Xenograft Studies 
Xenograft studies were performed in accordance with the standards of the 
Institutional Animal Care and Use Committee (IACUC) under a protocol approved by 
the Animal Care and Use Committee of Massachusetts General Hospital. Nude mice 
(nu/nu; 6-8 weeks old; Charles River Laboratories) were anesthetized using a 2% 
Isoflurane (Baxter) inhalation oxygen mixture. A suspension of 5x106 H1975 cells (in 
0.2 ml of PBS) was inoculated subcutaneously into the lower-left quadrant of the 
flank of each mouse. Once the mean tumor volume reached ~500 mm3 AZD6244 
was administered by oral gavage in 3 doses of 25mg/kg over 30 hours. Tumors were 
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measured twice weekly using calipers, and volume was calculated using the formula 
(length x width2 x 0.52).  Mice were monitored daily for body weight and general 
condition. The experiment was terminated when the mean size of either the treated 
or control groups reached 2000 mm3 (Faber et al., 2009).   
qRT-PCR  
 RNA was isolated from HCC827 and BT-474 cells using the RNEasy RNA 
isolation kit (Qiagen) and cDNA was transcribed from 2 g total RNA with 
Superscript II Reverse Transcriptase (Invitrogen) and used as a template for 
subsequent PCR amplifications.  The relative copy number for ERBB3 and HRG was 
determined using quantitative real time PCR using a lightcycler 480 (Roche) as 
previously described (Faber et al., 2009). The PCR primers and conditions are 
available upon request. 
siRNA and Transient Transfections  
 ERBB3 s4779 silencer select validated siRNA and silencer negative control 
siRNA were purchased from Ambion (Austin, TX).  Cells were seeded on a 6-well 
plate for Westen blot or a 6cm plate for FACS in DMEM media without penicillin or 
streptomycin.  Cells were transfected with 50nM siRNA with using HiPerFect 
Transfection Reagent (Qiagen) according to manufacturer’s instructions. 
CHO-KI cells were seeded in six-well plates at 50% confluency. Transient 
transfections were performed with TransIT®-LT1 Transfection Reagent (Mirus Bio 
LLC, Madison, WI) according to the manufacturer’s recommendations. Wild type 
ERBB3 was co-transfected with an equal ratio of GFP, wild type EGFR, wild type 
HER2, EGFR T669A or HER2 T677A. 
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shRNA Constructs, DNA Constructs and Lentiviral Production 
 The EGFR shRNA hairpin #4705 targeting the 3’ UTR (sequence: 5’-CCGG-
AGAATGTGGAATACCTAAGG-TTTTG-3’) was purchased from Dr. Toshi Shoda 
(Mass General Hospital, Molecular Profiling Laboratory, Charlestown, MA) in the 
pLKO-puro vector backbone and has been previously described (Rothenberg et al., 
2008). The ERBB3 shRNA hairpin #475 (Engelman et al., 2005), sequence: 5’-
CCGG-AATTCTCTACTCTACCATTGCCTC-GAGGCAATGGTAGAGTAGAGAATT-
TTTTG-3’) was provided by Dr. William Hahn (RNAi Consortium, Boston, MA). The 
ERBB3 shRNA hairpin was introduced into the inducible tet-on PLKO vector. For the 
shERBB3 studies, HCC827 cells were infected as previously described (Engelman et 
al., 2005; Rothenberg et al., 2008) with tet-on PLKO shERBB3 and tet-on PLKO 
scramble control shRNA (Addgene Cambridge, MA) knockdown vectors and 
selected in 2 g/L puromycin.  
 The human EGFR (wild type and exon 19del) and HER2 cDNA coding regions 
were cloned into the pENTR/D-TOPO vector (Invitrogen) and the T669A and T677A 
mutants were constructed with Quick Change Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s instructions and as previously 
described (Engelman et al., 2006b). All constructs were confirmed by DNA 
sequencing.  EGFR and HER2 wild type, T669A and T677A mutant constructs, and 
a GFP vector control were cloned into the plenti-IRES-GFP lentiviral vector 
(Addgene, Cambridge, MA) and infections were performed as described previously 
(Engelman et al., 2006b). 
Flow Cytometry  
 BT-474 cells were transfected with ERBB3 siRNA (Ambion) for 48 hours and 
then treated with AZD6244 or GDC-0941 for 48 hours.  Following treatment, cells 
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were collected and stained with propidium iodide (PI) and Annexin V as described 
previously (Faber et al., 2006). Cells analyzed using a BD LSR 3 analytical flow 
cytometer (BD Biosciences).  Percent apoptosis was calculated using the sum of 
Annexin V positive and PI/Annexin V double positive cells. 
Tandem mass spectrometry (LC/MS/MS) 
 For targeted mass spectrometry (MS) experiments, EGFR or HER2 proteins 
were immunoprecipitated from HCC827 or BT-474 cells that were treated with 
AZD6244. Proteins were immunoprecipated overnight using anti-EGFR antibody 
(Santa Cruz) or an anti-HER2 antibody, respectively, and were separated using 
SDS-PAGE, stained with Coomassie blue, and bands were excised. Samples were 
prepared and analyzed by reversed-phase microcapillary/tandem mass spectrometry 
(LC/MS/MS) as described previously (Dibble et al., 2009; Egan et al., 2011; Zheng et 
al., 2009). Peptide ions representing from EGFR predicted Thr669 phosphorylation 
and non-phosphorylated sites were targeted in MS/MS mode for quantitative 
analyses using the following ions (Non-PO4: 678.70, 3+ and 1017.55, 2+, PO4: 
705.36, 3+ and 1057.53, 2+). For the HER2 Thr677 site, the following ions were 
used [Non-PO4: 885.12, 3+; 890.44, 3+(+16 Msx); 895.77, 3+(+32 Msx); PO4: 
911.77, 3+; 917.10, 3+(+16 Msx); 922.43, 3+(+32, 2  Msx)]. MS/MS spectra collected 
via CID were searched against the concatenated target and decoy (reversed) Swiss-
Prot protein database using Sequest (Proteomics Browser Software, Thermo 
Scientific) with differential modifications for Ser/Thr/Tyr phosphorylation (+79.97) and 
differential modification of Met oxidation (+15.99, Msx). Phosphorylated and 
unphosphorylated peptide sequences were identified if they initially passed the 
following Sequest scoring thresholds against the target database: 1+ ions, Xcorr 
2.0 Sf  0.4, P  5; 2+ ions, Xcorr  2.0, Sf  0.4, P  5; 3+ ions, Xcorr  2.60, Sf 
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0.4, P  5 against the target protein database with mass accuracy less than 15 ppm.  
Manual inspection and determination of the exact sites of phosphorylation was 
confirmed using FuzzyIons and GraphMod software (Proteomics Browser Software, 
Thermo Scientific). False discovery rates (FDR) of peptide hits (phosphorylated and 
non-phosphorylated) were estimated below 1.0% based on reversed database hits. 
Relative quantification of phosphorylated peptide signal levels was 
performed as described previously (Dibble et al., 2009; Egan et al., ; Zheng et al., 
2009) using the following equations: 
TICPO4/(TICPO4+TICnonPO4) = Ratio of phosphopeptide signal (RPO4) 
These ratios of phosphopeptide signal were then compared to the same 
phosphopeptide ratios from the untreated samples according to the following 
equation: 
[(RPO4Treated/RPO4Untreated)-1] x 100 = % change in phosphorylation upon 
treatment 
4.4 Results 
MEK inhibition leads to activation of ERBB3/PI3K/AKT. 
 We had previously observed that AKT phosphorylation increased in response 
to MEK inhibition in HER2 amplified and EGFR mutant cancers (Faber et al., 2009). 
To determine whether this potential feedback is observed in in multiple cancer 
models with addiction to EGFR or HER2, we treated a panel of HER2 amplified or 
EGFR mutant cell lines with the MEK inhibitor AZD6244.  In each cell line, we 
observed a substantial increase in AKT phosphoylation at both S473 and T308 
residues, as well as increased phosphorylation of several downstream targets of 
AKT including GSK3, GSK3, ATP citrate lyase, and PRAS40 (Figure 17A).  We 
confirmed that the increased phosphorylation of these proteins was indeed a 
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consequence of increased AKT activation, as co-treatment with an allosteric AKT  
inhibitor blocked MEK inhibitor induced increases in their phosphorylation (Figure 
17B).  Of note, we observed that MEK inhibition led to significant up-regulation of 
phospho-C-RAF and phospho-MEK (Figure 17A), suggesting the possibility of 
activation of a common upstream signaling molecule leading to activation of both 
RAF and PI3K signaling.  To determine if this feedback mechanism was observed in 
vivo as well, we treated an EGFR-mutant H1975 (L858R/T790M) xenograft model 
with AZD6244 and observed increased phosphorylation of AKT in tumor lysates 
(Figure 17C).  
64
The increase in AKT phosphorylation suggested that there could be a change 
in the abundance of PIP3. To directly examine this possibility, we isolated lipids from 
EGFR-driven HCC827 and HER2-driven MDA-MB-453 cells and quantified PIP3
levels in the presence or absence of a MEK inhibitor.  In both cell lines we observed 
significant increases in PIP3 levels in cells treated with AZD6244 (Figure 18A).  The 
increased amount of PIP3 could be secondary to increased production or decreased 
degradation. We did not observe any change in expression of the PTEN 
phosphatase, the 3’ phosphatase responsible for de-phosphorylating PIP3 regulation 
of PI3K signaling (Figure 17A).  To determine whether the increases we observed in 
AKT phosphorylation might be due to increased PI3K activation, we 
immunoprecipitated the p85 regulatory subunit of PI3K to assess whether there was 
an increase in the abundance of upstream adaptors.  We found that treatment with 
AZD6244 increased binding of PI3K adaptors including ERBB3 and GAB1 in multiple 
cell lines, suggesting an increase in PI3K engagement with phospho-tyrosine 
proteins (Figure 18B). These results are consistent with the notion that MEK 
inhibition leads to activation of phospho-tyrosine signaling cascades that directly 
activate PI3K, which in turn increases the abundance of PIP3, ultimately leading to 
activation of AKT and its downstream substrates. 
In EGFR and HER2-driven cell lines, ERBB3 serves as a primary activator of 
PI3K/AKT signaling (Engelman et al., 2005; Hsieh and Moasser, 2007), and we 
observed increased ERBB3 binding to PI3K following MEK inhibition (Figure 18B).  
This led us to investigate whether treatment with a MEK inhibitor also led to 
increased ERBB3 tyrosine phosphorylation.  Indeed, we observed that MEK 
inhibition substantially increased tyrosine phosphorylated ERBB3 levels (Figure 
17A), consistent with the increased binding observed between ERBB3 and PI3K 
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upon MEK inhibitor treatment (Figure 18B).  In some cancer cell lines, we observed 
an increase in total ERBB3 along with phospho-ERBB3 (Figure 17A).  Of note, we 
did not observe a change in expression of the E3-ubiquitin ligase, neuregulin 
receptor degradation protein 1 (NRDP1), which has been shown to control the 
steady state levels of ERBB3 (Figure 17A) (Carraway, 2010; Diamonti et al., 2002). 
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To assess the kinetics of this feedback response, we treated the EGFR-
mutant HCC827 cell line with AZD6244 for a time course ranging from 1 to 24 hours.   
Phosho-ERBB3 and phospho-AKT, as well as activation of downstream substrates, 
increased after just one hour of MEK inhibition.  Feedback activation continued to 
accumulate over the next several hours, and persisted for 24 hours (Figure 19A).  
Next, to determine if the feedback activation of ERBB3 occurs on the plasma 
membrane, we biotin-labeled the surface of HCC827 cells in the presence or 
absence of AZD6244 and immunoprecipitated these labeled proteins for analysis by 
Western blot.  After just one hour of MEK inhibition during biotin labeling at 4 
degrees, surface levels of the activated receptor were significantly elevated (Figure 
19B). We also observed increased levels of total ERBB3 on the cell surface following 
AZD6244 treatment.  MEK inhibition did not seem to significantly affect the kinetics of 
loss of phospho- or total ERBB3 on the cell surface (Figure 19B), suggesting that 
receptor internalization or cycling was not significantly affected by MEK inhibition.  
An increase in total protein levels of ERBB3 and other RTKs via 
transcriptional up-regulation has been demonstrated as a common mechanism of 
feedback activation (Chakrabarty et al., 2011; Chandarlapaty et al., 2011).  However, 
the rapid kinetics of MEK feedback on increasing ERBB3 phosphorylation does not 
favor a transcriptional mechanism for this feedback.  To confirm that the increase in 
phospho and total ERBB3 levels following MEK inhibition was post-transcriptional, 
we measured ERBB3 mRNA levels by qPCR following treatment with AZD6244 for 6 
and 24 hours.  As predicted, we did not observe any change in ERBB3 mRNA levels 
in HCC827 or BT-474 cells treated with AZD6244 (Figure 19C).  These data suggest 
that MEK inhibition leads to increased ERBB3/PI3K/AKT signaling in multiple EGFR 
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and HER2-driven cancer cell line models, and that this feedback mechanism 
involves post-transcriptional activation of ERBB3.   
Knockdown of ERBB3 abrogates MEK/ERK feedback on AKT and downstream 
substrates. 
 To determine if increased phosphorylation of ERBB3 plays a significant role 
in the activation of AKT following MEK inhibition, we suppressed expression of  
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ERBB3.  In EGFR-mutant HCC827 cells we introduced a Tet-inducible shERBB3  
hairpin construct.  Following treatment with doxycycline there was effective 
knockdown of ERBB3, and this abrogated the increase in AKT signaling normally  
observed in HCC827 cells following MEK inhibition (Figure 20A).  In HER2 amplified 
BT-474 cells we used siRNA to knockdown ERBB3.  Similar to our observations in 
HCC827 cells, the increase in AKT signaling following MEK inhibition was attenuated 
in BT-474 cells lacking ERBB3 expression (Figure 20B). In contrast to HCC827 cells, 
we also observed significant down-regulation of basal AKT signaling in BT-474 cells 
following ERBB3 knockdown (Figure 20B), which indicates the sole reliance on 
ERBB3 for PI3K activation in this HER2 amplified cancer.  In contrast, EGFR mutant 
cancers also utilize GAB1 to activate PI3K (Figure 18B) (Engelman et al., 2005; 
Turke et al., 2010). 
 We expected that knockdown of ERBB3 would increase the efficacy of MEK 
inhibition since it would lead to suppression of PI3K/AKT signaling as well. We used 
PI/Annexin staining to assess induction of apoptosis in BT-474 cells following 
treatment with a MEK inhibitor alone, ERBB3 siRNA alone, or the combination.  
Single agent MEK inhibition did not cause any significant cell death in BT-474 cells 
compared to cells grown in media alone; however, knockdown of ERBB3 caused a 
modest induction of apoptosis. The addition of the MEK inhibitor to cells treated with 
ERBB3 siRNA increased this cell death response, approaching the level of apoptosis 
achieved in cells treated with a PI3K inhibitor, GDC-0941, in combination with 
AZD6244 (Figure 20C).  These data indicate that ERBB3 plays a significant role in 
MEK feedback on PI3K/AKT signaling in EGFR and HER2-driven cell lines, and 
suggests that combination therapies targeting MEK and PI3K, or MEK and ERBB3, 
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may block feedback activation of ERBB3/PI3K/AKT signaling and thus be more 
effective than treatment with a MEK inhibitor alone. 
MEK inhibition results in feedback activation of ERBB3 even in KRAS-mutant cell 
lines with low basal levels of phospho-ERBB3. 
We next determined whether MEK feedback on ERBB3 also occurs in other  
cancers models not addicted to EGFR or HER2.  We treated a panel of KRAS- 
mutant cell lines, which have low basal levels of phospho-ERBB3, with AZD6244.   
Surprisingly, MEK inhibition led to significant activation of ERBB3, but in contrast to 
the EGFR mutant and HER2 amplified cancers, the increase in ERBB3 activation did 
not translate to increased AKT signaling (Figure 21A).  Similar to the EGFR and 
HER2 driven models, we also observed feedback up-regulation of phospho-C-RAF 
and phospho-MEK following MEK inhibition. We suspect that the increase in ERBB3 
phosphorylation did not drive PI3K in these models simply because these KRAS- 
mutant cell lines express significantly less EGFR and HER2, resulting in markedly 
less absolute levels of phospho-ERBB3 compared to those observed in the EGFR 
and HER2-driven models discussed above (Figure 21B).  Thus, the feedback from 
MEK inhibition to activation of ERBB3 phosphorylation appears to be conserved in 
many cancer models, but results in increased PI3K/AKT signaling only in cell lines 
that express sufficient basal levels of phospho-ERBB3. 
The feedback that we observe upon MEK inhibition appears to be distinct 
from a well-described feedback mechanism in which TORC1 inhibition leads to 
increased expression of the IRS-1 adaptor protein and subsequent up-regulation of 
IGF-IR/IRS signaling (Carracedo et al., 2008; O'Reilly et al., 2006).  In the KRAS-
mutant cell lines that we analyzed, the IGF-1R/IRS was the main activator of the 
PI3K/AKT pathway as we have described previously (Figure 21C) (Ebi et al., 2011),  
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and treatment with the mTORC1 inhibitor rapamycin led to feedback activation of 
AKT signaling that was blocked by co-treatment with the IGF-IR/IR inhibitor, NVP-
AEW541 (Figure 21A, C).  The MEK inhibitor-induced activation of ERBB3 in the 
KRAS mutant cancers was blocked by gefitinib, but not NVP-AEW541 (Figure 21C).  
Similarly, NVP-AEW541 did not impair the AZD6244-induced activation of AKT 
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phosphorylation in the EGFR and HER2-driven cell lines (Figure 21D).  Together 
these data indicate that feedback activation of ERBB3 following MEK inhibition 
occurs in a broad range of cancers, but this only leads to activation of AKT in a 
subset of cancers (e.g., EGFR mutant lung and HER2 amplified breast cancers).  
Further, the effect of MEK inhibition on ERBB3 is a novel feedback mechanism 
distinct from TORC1 feedback on IRS-1.  A model describing these findings is shown 
in Figure 22. 
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MEK inhibition results in increased tyrosine phosphorylation of EGFR and HER2 due 
to inhibition of ERK-mediated threonine phosphorylation of these receptors. 
Based on these results, we investigated the mechanism by which treatment 
with the MEK inhibitor leads to increased ERBB3 phosphorylation. We did not 
observe a change in the expression of HRG ligand protein or mRNA as measured by 
ELISA and qPCR, respectively (Figure 23A, B).  However, we also observed that the  
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MEK inhibitor-induced feedback activation of AKT phosphorylation required EGFR 
and HER2 kinase activity (Figure 23C, D).  Indeed, even in the KRAS mutant  
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SW1463 cells, MEK feedback on ERBB3 was still dependent on EGFR kinase 
activity (Figure 21C).  
Because inhibition of EGFR and HER2 blocked the effect of MEK feedback 
activation of ERBB3/PI3K/AKT signaling, we investigated whether MEK inhibition  
was also directly effecting the activation of EGFR and HER2.  We treated HCC827  
and BT-474 cells with AZD6244 for 6 or 24 hours and observed increased tyrosine  
phosphorylation of both EGFR and HER2, indicative of receptor activation (Figure 
24A).  It has been reported that activation of EGFR involves the formation of an 
asymmetric dimmer in which the N-terminal lobe of the “receiver/acceptor” kinase 
interacts with the C-terminal lobe of the “activator/donor” kinase, allowing for tyrosine 
phosphorylation and activation of both RTKs by the “receiver/acceptor”, which has 
been instilled with kinase activity by the “activator/donor” (Hubbard, 2009). 
Importantly, formation of the active RTK dimmer is facilitated by stabilizing contacts 
made between the juxtamembrane (JM) domain of the “receiver/acceptor” and the C-
terminal lobe of the “activator/donor” kinase (Hubbard, 2009; Jura et al., 2009; Red 
Brewer et al., 2009). Threonine 669, a putative MAPK target site, is conserved within 
the JM domain of EGFR, HER2, and ERBB4 and may regulate dimerization 
dynamics (Li et al., 2008; Northwood et al., 1991; Red Brewer et al., 2009; Takishima 
et al., 1991).  
Thus, we hypothesized that the MEK-ERK signaling pathway may suppress 
trans-phosphorylation of ERBB3 by directly phosphorylating EGFR and HER2 in the 
JM domains. We used tandem mass spectrometry to determine if phosphorylation of 
this JM domain threonine residue was lost following treatment with AZD6244.  We 
immunoprecipitated the corresponding RTKs from cell treated with AZD6244 and 
directly analyzed phosphorylation of this conserved threonine residue by targeted 
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LC/MS/MS.  By targeting both the phosphorylated and non-phosphorylated peptide 
forms, we observed a 66% average decrease in the level of T669 phosphorylation of 
EGFR, and a 75% decrease in the level of T677 phosphorylation of HER2 upon 
treatment with AZD6244  (Figure 24B). Antibodies specific to these JM 
phosphorylation sites confirmed that treatment with AZD6244 led to loss of 
phosphorylation of T669 of EGFR and the analogous T677 of HER2 (Figure 24A).  
Together these data indicate that loss of this inhibitory threonine phosphorylation on 
the JM domains of EGFR and HER2 occurs in our cell line models following MEK 
inhibition.  
Mutation of T669 and T677 abrogates MEK inhibitor-induced suppression of ERBB3 
activation. 
 Based on the results discussed above, we hypothesized that MEK inhibition 
activates AKT by decreasing ERK1/2 phosphorylation, which in turn blocks an 
inhibitory threonine phosphorylation on the JM domains of EGFR and HER2, thereby 
increasing phosphorylation of ERBB3.  To test this hypothesis, we expressed wild 
type ERBB3 with either wild type EGFR or mutant EGFR T669A in CHO-KI cells, 
which do not express ERBB receptors endogenously.  In cells expressing wild type 
EGFR, MEK inhibition led to feedback activation of phospho-ERBB3 and phosho-
EGFR, recapitulating the results we had observed in our panel of cancer cell lines 
(Figure 25A).  However, in contrast, the EGFR T669A mutant led to a basal increase 
in both EGFR and ERBB3 tyrosine phosphorylation, and this was not augmented by 
MEK inhibition.  As a control, we treated CHO-KI cells expressing the EGFR T669A 
mutant with 50ng/mL of HRG ligand to induce ERBB3 phosphorylation.  In response 
to HRG stimulation we achieved a further increase in ERBB3 activation (Figure 25A).  
This indicated that the lack of induction of phospho-ERBB3 in EGFR T669A 
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expressing cells following MEK inhibition was not simply due to the fact that we had 
saturated the system with maximum ERBB3 activation.  We observed analogous 
results in CHO-KI cells expressing wild type ERBB3 in combination with wild type or 
the T677A mutant HER2 receptor (Figure 25B). Together these results support the  
hypothesis that inhibition of phosphorylation of a conserved threonine residue within  
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the JM domains of EGFR and HER2 leads to feedback up-regulation of ERBB 
receptor activation (Figure 26). 
To confirm that this feedback model explains the activation PI3K signaling in 
EGFR mutant cancers, we used an shRNA system to knockdown endogenous 
EGFR (which carries an exon 19 deletion) in the EGFR-mutant HCC827 (exon 
19del) NSCLC cell line and replaced with either EGFR (exon 19del) wild type at 
T669, or EGFR (exon 19del) carrying a T669A mutation.  Of note, this is the same 
cell line in which we determined that EGFR T669 is phosphorylated in MEK-
dependent manner (Figure 24).  In parental HCC827 cells, MEK inhibition leads to  
significant feedback activation ERBB3/PI3K/AKT signaling (Figures 17 and 18), and 
when endogenous EGFR was replaced with an EGFR (exon19del) construct wild 
type at T669 we saw similar results (Figure 25C).  However, replacement with the 
EGFR (exon19 del) T669A mutant led to increased tyrosine phosphorylation of both 
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EGFR and ERBB3 and activation of PI3K/AKT signaling, mimicking the effect of 
MEK inhibition (Figure 25C).  These results demonstrate that the phosphorylation of 
T669 is necessary for MEK/ERK to suppress EGFR-mediated activation of ERBB3.  
This supports the hypothesis that ERK feedback on ERBB3/PI3K/AKT and RAF/MEK 
signaling is mediated though phosphorylation of T669 on EGFR.  In our EGFR and 
HER2-driven cancer cell lines, increased receptor activation translates to increased 
phosphorylation of ERBB3 and up-regulation of downstream PI3K/AKT signaling. 
4.5 Discussion 
RAF and MEK inhibitors are currently being developed for treatment of 
cancers with persistent activation of RAF/MEK/ERK signaling.  However, the efficacy 
of these drugs as single agents has been underwhelming to date.  Although there 
are several potential reasons for this lack of efficacy, feedback activation of parallel 
oncogenic pathways including PI3K/AKT signaling has been invoked as a potential 
limitation (Faber et al., 2009; Hoeflich et al., 2009; Mirzoeva et al., 2009).  This idea 
is analogous to the findings that TORC1 inhibitors are limited by feedback activation 
of PI3K signaling (O'Reilly et al., 2006).  In this study, we show that MEK feedback 
on ERBB receptors occurs in multiple cell line models.  We propose a mechanism for 
this feedback in which MEK inhibition blocks threonine phosphorylation of a direct 
ERK target site in the conserved JM domains of EGFR and HER2.  Phosphorylation 
of this threonine residue has been shown to impair receptor activation (Red Brewer 
et al., 2009). Therefore, relief from this negative feedback, through MEK inhibition 
leads to increased ERBB signaling and activation of downstream effectors including 
PI3K/AKT signaling.  
Our findings suggest that direct phosphorylation of EGFR T669 and HER2 
T677 by MEK/ERK signaling suppresses activation of ERBB3.  Previous data 
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suggests that phosphorylation of these residues impairs dimerization and activation 
(Li et al., 2008; Red Brewer et al., 2009). Our findings agree with those by Li and 
colleagues who expressed EGFR T669A mutant homodimers in CHO-KI cells and 
observed no additive effect on tyrosine phosphorylation of this EGFR mutant with the 
addition of a MEK inhibitor (Li et al., 2008).  In addition to increased ERBB3 tyrosine 
phosphorylation, we also observe increased expression of total ERBB3 protein 
following MEK inhibition.  This increase appears to be post-transcriptional as no 
change in ERBB3 mRNA levels was observed following treatment with AZD6244 
(Figure 19C).  We were unable to definitively determine the mechanism for increased 
expression of total ERBB3. We hypothesize that ERBB3 protein levels become 
elevated following MEK inhibition because loss of T669/T677 phosphorylation allows 
for stronger EGFR-ERBB3 or HER2-ERBB3 dimer formation and increased receptor 
stability.  Increased ERBB3 expression was not caused by increased tyrosine 
phosphorylation of ERBB3.  In KRAS-mutant SW1463 cells treated with AZD6244 in 
combination with an EGFR inhibitor, total ERBB3 levels remained elevated despite 
potent inhibition of ERBB3 tyrosine phosphorylation (Figure 21C).  Indeed, ERK 
phosphorylation of the threonine sites appeared to be necessary for this effect.  For 
example, expression of the T669A mutant EGFR in both the CHO-KI cells and the 
HCC827 cells led to an increase in basal ERBB3 levels, which was not further 
increased by the addition of a MEK inhibitor (Figure 25).  These results suggest that 
increases in ERBB3 protein levels are dependent on EGFR threonine 
phosphorylation at residue 669 in the JM domain, and are likely a result of improved 
dimerization and receptor stability.   
 In EGFR and HER2-driven cancers, both the PI3K/AKT and RAF/MEK 
signaling pathways are activated by the respective RTKs, and the ERBB3 receptor 
scaffold is used as a primary activator of PI3K signaling.  HER2-driven cancers have 
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demonstrated sensitivity to single agent PI3K inhibitors; however single agent MEK 
inhibitors or alternative therapeutic strategies that do not block phosphorylation of 
AKT are largely ineffective in inducing apoptosis (Brachmann et al., 2009; Serra et 
al., 2008; She et al., 2008). In contrast, EGFR-driven cancers require inhibition of 
both PI3K/AKT signaling and RAF/MEK signaling for induction of cell death (Faber et 
al., 2009).  In this study, we show that feedback up-regulation of ERBB3 occurs in 
multiple EGFR mutant and HER2 amplified cell line models and that this response 
translates to activation of downstream PI3K/AKT signaling.  Our data provides 
mechanistic insights into the previous findings that MEK feedback on AKT is 
dependent on ERBB signaling in human gastric cells (Yoon et al., 2009).  These 
results suggest that combining MEK inhibitors with either ERBB inhibitors, or PI3K 
inhibitors, may be effective therapeutic strategies in the clinic.  Furthermore, although 
there are currently no approved therapies targeting ERBB3, pre-clinical development 
of anti-ERBB3 antibodies is underway and our data points to the possible utility of 
combining these therapeutic antibodies with MEK inhibitors to block feedback 
activation of AKT in multiple cancer models. 
 Interestingly, we also observed feedback activation of ERBB3 following MEK 
inhibition in KRAS-mutant cancers that express low basal levels of phosphor-ERBB3 
and therefore do not use ERBB3 to activate PI3K.  This observation suggests that 
MEK feedback on ERBB3 occurs in a broad range of cancers, regardless of 
dependence on ERBB signaling, and highlights another potential complication for 
patients treated exclusively with inhibitors of the RAF/MEK/ERK pathway.  For 
example, in KRAS-mutant or BRAF-mutant cancers that initially respond to single 
agent RAF or MEK inhibitors, chronic inhibition of this pathway may lead to activation 
of EGFR or HER2 and the development of a dependence on these pathways that 
was not present before treatment.  Therefore, these data suggest a possible 
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mechanism of acquired resistance to single agent RAF or MEK inhibitors.
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Chapter 5- General Discussion
5.1 Summary of Results 
In this thesis my colleagues and I describe a novel resistance mechanism in 
multiple EGFR-driven NSCLC models in which expression of HGF ligand leads to 
activation of MET signaling in the absence of MET amplification. In these models, 
activation of MET via ligand leads to maintenance of GAB1/PI3K/AKT signaling as 
well as MEK/ERK signaling despite sustained EGFR inhibition, and treatment with a 
combination of an EGFR inhibitor and a MET inhibitor is necessary to restore 
sensitivity in the presence of HGF.  Further, we show that MET amplification 
preexists in a small subpopulation of the parental HCC827 NSCLC cell line, and that 
selection of these MET amplified cells in the presence of an EGFR inhibitor 
consistently leads to the development of MET amplification as a resistance 
mechanism. Further, we showed that the presence of HGF ligand dramatically 
accelerated the kinetics of selection of preexisiting MET amplified cells.  Transient 
exposure to HGF allowed cells to become stably resistant and ligand-independent 
after just two weeks of treatment with an EGFR inhibitor. 
We also performed analysis of paired tumor samples from NSCLC patients 
with acquired resistance to gefitinib and found that detection of preexisting MET
amplified cells in gefitinib sensitive pre-treatment samples allowed us to predict 
whether a patient would develop MET amplification following treatment with an 
EGFR inhibitor in the clinic. High HGF expression levels also correlated significantly 
with gefitinib resistance in NSCLC patient samples.  Together, these results suggest 
the utility of using a combination of a MET inhibitor and an EGFR inhibitor in patients 
with high HGF expression levels, as well as in treatment naïve patients with 
preexisting subpopulations of MET amplified cells. 
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PI3K/AKT and MEK/ERK signaling cascades are intricately connected by an 
array of feedback loops that regulate flux through these pathways.  In this thesis my 
colleagues and I describe a feedback loop in which MEK inhibition leads to activation 
of ERBB3/PI3K/AKT signaling.  We present a novel mechanism for this effect in 
which treatment with a MEK inhibitor blocks direct ERK phosphorylation of a 
conserved threonine residue in the juxtamembrane domains of EGFR and HER2.  
Loss of this inhibitory threonine phosphorylation leads to increased RTK activation 
and up-regulation of downstream effectors including increased ERBB3 
phosphoryation, PIP3 production and phosphorylation of AKT and its substrates.  
This feedback occurs in multiple cell line models, including KRAS-mutant cancers, 
regardless of whether ERBB3 normally drives PI3K/AKT signaling.  In pre-clinical 
studies, single agent MEK inhibitors have been shown to be less effective in cases 
where treatment leads to up-regulation of AKT phosphorylation (Hoeflich et al., 2009; 
Mirzoeva et al., 2009) and these cancers may be more effectively treated with a 
combination of a MEK inhibitor and a PI3K inhibitor or RTK inhibitor.  Of note, in 
cancers that do not use ERBB receptors to drive PI3K/AKT signaling, chronic 
treatment with a MEK inhibitor may lead these cells to become dependent on EGFR 
or HER2 and shift to use ERBB signaling to maintain PI3K activation and other 
downstream effectors as mechanisms of survival. 
5.2 PI3K/AKT and RAF/MEK/ERK Signaling in Cancer4
The importance of PI3K/AKT and MEK/ERK signaling for cancer cell survival, 
growth, proliferation and metabolism has been well established (Davies et al., 2002; 
Engelman, 2009; Montagut and Settleman, 2009; Samuels et al., 2004).  In many 
                                                
4 Excerpts and figures from this section were published in Yang, et al. Cancer Research
September 2011.
84
cases, targeted therapies are effective when treatment leads to down-regulation of 
both of these central oncogenic pathways (Engelman et al., 2008; Faber et al., 
2009), and conversely the development of resistance is commonly associated with 
reactivation of one or both of these pathways.  However, it is still unclear why in 
some cancers single agent inhibitors are effective; e.g., HER2 amplified breast 
cancers tend to respond to treatment with a PI3K inhibitor alone (Faber et al., 2010; 
Ihle et al., 2009; Serra et al., 2008; She et al., 2008), and BRAF mutant cancers 
often respond to single agent BRAF or MEK inhibition (Flaherty et al., 2010; 
McDermott et al., 2007; Solit et al., 2006). In other cancer models including EGFR
mutant NSCLC, it is often necessary to inhibit both PI3K/AKT and MEK/ERK 
signaling in order to achieve growth arrest and apoptosis (Faber et al., 2009).  It has 
been suggested that cancer cells become most dependent on those pathways that 
regulate mTORC1 in a particular model, and in some cases one pathway is 
predominant while in others both PI3K and MEK/ERK seem to drive mTORC1 
signaling and downstream effectors (Ebi et al., 2011; O'Brien et al., 2010).  As 
discussed above, when we consider the use of both MEK inhibitors and PI3K 
inhibitors as single agents it will be critically important to be aware of the complex 
feedback networks that link these two pathways, as inhibition of a single effector 
often leads to up-regulation of a parallel pathway. 
Because of the well-established role for PI3K/AKT signaling in human 
cancers, there is an increased effort to identify activators of PI3K in order to inform 
the most effective treatment strategies.  In some cancers, PI3K is activated by direct 
mutation, but more commonly it is activated by mutation or amplification of upstream 
receptor tyrosine kinases. In collaboration with Dr. John Asara (BIDMC Mass 
Spectrometry Core Facility, Boston, MA) my colleagues and I developed and 
validated a systematic method to determine which RTK signaling cascades activate 
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PI3K in certain cancers (Yang et al., 2011).  Traditional techniques often involve 
immunoprecipiation of the p85 regulatory subunit of PI3K followed by repeated 
Western blotting for co-immunoprecipitating adaptors.  However, this approach is 
relatively time consuming, non-quantitative, and requires specific antibodies for each 
candidate activator of PI3K.   
Our group recently identified a quantitative tandem mass spectrometry 
(LC/MS/MS) approach that identifies upstream activators of PI3K both in vitro and in 
vivo (Yang et al., 2011).  We validated this method in a number of systems including  
a human cancer cell line with acquired gefitinib resistance mediated through IGFR 
signaling, an ALK-driven NSCLC xenograft model which uses IRS-1 and IRS-2 to 
activated PI3K, and a cell line model in which we identified the presence of an 
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E454K mutation in the p110 subunit of PI3K.  We also tested this approach in the 
HCC827 cell line treated with gefitinib and HGF ligand and showed that HGF 
treatment rescues GAB1 and GAB2, but not ERBB3, binding to PI3K (Figure 27). 
Having an efficient high throughput method to assess activators of this pathway will 
be useful in helping to guide the selection of tyrosine kinase inhibitors for 
personalized therapies. 
  
5.3 Biomarkers and Personalized Medicine5
With the development of molecular targeted therapies, cancer biology has 
begun to transition towards personalized medicine.  This new field uses diagnostic 
tests to identify the specific genes, proteins and pathways driving a particular cancer 
with the goal of determining individualized treatment strategies for each patient.  
Ultimately, distinguishing individual patients based on the genetic and molecular 
characteristics of their tumors will allow us to design and conduct more efficient 
clinical trials leading to faster, less costly drug approvals, and better therapeutic 
options for patients.  Further, prospectively identifying which patients are likely to 
respond to a particular targeted therapy will reduce unnecessary toxicities incurred 
by patients who are unlikely to receive any benefit from treatment.   The future of 
personalized medicine will continue to improve as more targets are identified, new 
therapies are designed and approved, and more efficient diagnostics become part of 
standard clinical practice. 
Numerous genetic and molecular biomarkers have already been identified to 
determine which patients will respond to specific targeted cancer therapies.  The 
EGFR tyrosine kinase inhibitors gefitinib and erlotinib were the first targeted 
                                                
5 Excerpts and figures from this section were published in Sequist, et al., Science 
Translational Med, March 2011.
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therapies to be approved for the treatment of NSCLC.  During the course of their 
clinical development, it has become clear that the substantial clinical benefit 
associated with EGFR TKIs is limited to a distinct subset of patients harboring EGFR
activating mutations (Paez et al., 2004; Pao et al., 2004).  A phase III clinical trial 
performed in treatment naïve patients with pulmonary adenocarcinoma and 
published in 2009 in the New England Journal of Medicine showed that gefitinib 
provided a modest clinical benefit as compared to carboplatin-palcitaxel 
chemotherapy (Mok et al., 2008).  However, when patients treated with gefitinib were 
separated according to EGFR mutational status, those with EGFR activating 
mutations had an objective response rate of 71.2%, whereas EGFR wild-type 
patients with an objective response rate of 1.1%.  Further, progression free survival 
was significantly longer in the mutation-positive subgroup treated with gefitinib 
compared to chemotherapy, but surprisingly, the opposite was true in the EGFR wild-
type subgroup and these patients had significantly poorer outcomes when treated 
with gefitinib (Mok et al., 2008).  These results suggest that EGFR mutational status 
is a critical biomarker for gefitinib response in NSCLC.
Additional biomarkers have also been validated to predict responsiveness to 
EGFR targeted therapies.  KRAS mutation as well as PTEN deletion and PIK3CA
mutation have all been correlated with poor response to RTK targeted therapies 
(Berns et al., 2007; Engelman et al., 2006b; Ludovini et al., 2011; Yamasaki et al., 
2007).  Faber et al. recently showed that expression levels of the pro-apoptotic 
protein BIM predict responsiveness to targeted therapies in multiple cancer models 
(Faber et al., 2011). The presence of preexisiting T790M mutant EGFR has 
previously been show to predict the development of gefitinib resistance (Inukai et al., 
2006).  Finally, the data presented in this thesis suggest that high levels of the HGF 
ligand correlate with a lack of responsiveness and a tendency to develop resistance 
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to EGFR targeted therapies, and that preexistence of a small sub-population of MET
amplified cells is a predictive biomarker for the development of MET amplification as 
a resistance mechanism to EGFR TKIs (Turke et al., 2010). 
 The identification of biomarkers to predict whether a drug is hitting its target in 
patients, and to quickly determine after initial treatment whether a patient is likely to 
respond to a specific targeted therapy, will also be useful.  It has recently been 
suggested that the phosphorylation status of the S6 ribosomal protein, a downstream 
effector of mTORC1, will be an informative biomarker to predict whether or not a 
patient will respond to a given targeted therapy.  For example, in breast cancer 
models treated with single agent PI3K inhibitors, a decrease in S6 phosphorylation 
has been shown to significantly correlate with sensitivity and tumor regressions 
(O'Brien et al., 2010). 
 As the number of biomarkers predicting responsiveness to targeted therapies 
grows, there is an increasing need for improved diagnostic techniques and frequent 
analysis of cancers as they evolve during treatment.  It will be essential for the future 
of personalized cancer medicine that efficient and cost effective diagnostic tests 
become the standard or care and that protocols are updated to encourage analysis 
of tumors both before treatment and as frequently as reasonably possible over the 
course of disease progression. 
 Our group recently published a study in collaboration with Dr. Lecia Sequist 
(Massachusetts General Hospital, Boston, MA) assessing the clinical progression at 
the molecular level of 37 NSCLC patients with EGFR activating mutations, initially 
exhibiting sensitivity but ultimately acquiring resistance to gefitinib (Sequist et al., 
2011).  Repeat biopsies of recurrent disease sites were performed over the course of 
disease as part of routine clinical care and molecular analyses were performed to 
assess the prevalence of established biomarkers and to identify new mechanisms of 
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resistance.  As predicted, known mechanisms of resistance including EGFR T790M 
mutation and the development of MET amplification were observed, and in three 
patients serial biopsies revealed that genetic mechanisms of resistance were lost in 
the absence of continued selective pressure of EGFR inhibitor treatment and such 
cancers were sensitive to a second round of treatment with EGFR inhibitors.  
Surprisingly, five resistant tumors transitioned from NSCLC to small-cell lung cancer 
(SCLC) and responded to standard SCLC treatments, and some resistant cancers 
showed unexpected genetic changes including EGFR amplification and mutations in 
the PIK3CA gene (Sequist et al., 2011).   
 In the laboratory, my colleagues and I observed a different phenotypic 
transformation when using the H1975 (L858R/T790M) lung adenocarcinoma cell line 
to model acquired resistance to an EGFR inhibitor. The cell line was made resistant 
to the irreversible EGFR inhibitor, PF00299804, to which it was initially sensitive 
(Figure 28A).  The resistant cell line (H1975 Resistant) did not acquire MET
amplification, but did show an increased copy number of the EGFR T790M allele, 
consistent with previous reports (Ercan et al., 2010). In addition, it underwent a 
marked histological change and developed a spindle-like morphology (Figure 28B).  
Assessment of E-cadherin and vimentin expression confirmed that the resistant cell 
line had undergone an epithelial-to-mesenchymal transition (EMT) (Figure 28C).  
EMT describes a cancer cell that loses its epithelial morphology and develops a 
more spindle-like mesenchymal morphology; this histological change is often 
associated with a shift in expression of specific proteins (for example, loss of E-
cadherin and gain of vimentin) and a more invasive phenotype. In contrast, 
HCC827GR cells that had developed MET amplification upon resistance to an EGFR 
TKI (Engelman et al., 2007b) did not undergo an EMT (Figure 28C).  
90
This finding supported previous observations that cancer cell lines undergoing 
an EMT have intrinsic resistance to EGFR inhibitors (Frederick et al., 2007; Fuchs et 
al., 2008; Rho et al., 2009; Thomson et al., 2005). This prompted us to analyze 
paired tissue samples from seven patients with unknown mechanisms of resistance 
for the development of mesenchymal features and changes in vimentin and E-
cadherin expression. Three of the seven resistant specimens had phenotypic 
changes consistent with a mesenchymal appearance at the time of TKI resistance. 
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Further analyses confirmed that two of these three post-treatment specimens had 
acquired vimentin expression and lost E-cadherin expression compared to their pre-
treatment counterparts, supporting an EMT (Figure 28D). 
Overall, this study of the progression of EGFR mutant cancers as they become 
resistant to first line targeted therapies underscores the importance of repeatedly 
assessing cancers throughout the course of the disease.  Of note, there were no 
major biopsy related complications observed during this study.  In fact, evidence 
from three patients with multiple biopsies over the course of their disease suggests 
that both tumor genotype and phenotype may evolve dynamically under the selective 
pressure of targeted therapies. Therefore, repeat tumor biopsies after the 
development of resistance should be performed whenever practical to provide 
current knowledge of the genetic and histological properties of a tumor and allow 
clinicians to identify the best treatment options for individual patients.  
5.4 Combination Therapies6
As we continue to identify more and more biomarkers and targets in oncology 
and develop a collection of targeted therapies, acquired resistance remains a 
significant and pervasive limitation to longer-term success in the clinic.  In an effort to 
combat resistance, numerous combination therapies are being explored.  Notably, 
combinations of specific PI3K inhibitors or dual PI3K/mTOR inhibitors with MEK 
inhibitors have been extensively tested in the laboratory (Engelman et al., 2008; 
Faber et al., 2009; Wong et al., 2010) and are beginning to enter clinical trials.  Both 
MET inhibitors and IGFR inhibitors are being combined with EGFR inhibitors in the 
clinic. These combination RTK targeted therapies may be useful either as first line 
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treatments in a subset of patients, or in patients with acquired resistance to gefitinib.  
Multiple HGF and ERBB3 targeted therapies are also under development and may 
be tested in combination with RTK inhibitors or therapies targeting downstream 
effectors.   
Several criteria are important to consider in the context of combination 
therapies.  First, when targeted therapies are combined in the clinic, significant side 
effects and toxicities become a concern, particularly when relatively high doses of an 
inhibitor are necessary to achieve target inhibition. Second, it is debated whether 
combination therapies should be given sequentially or simultaneously, and whether 
each drug should be given at a moderate dose at regular intervals or at a high pulsed 
dose less frequently (Shah et al., 2008). Finally, it has been suggested that 
successful therapies often lead to both growth arrest as well as apoptosis of cancer 
cells.  To this point, preliminary studies in our laboratory and others have begun to 
explore the use of drugs designed to induce a cell death response (e.g., cytotoxic 
chemotherapies, or pro-apoptotic protein mimetics) in combination with targeted 
therapies shown to induce a cytostatic effect.  
In a recent commentary (Turke and Engelman, 2010) we discuss the need for 
more rigorous criteria for defining whether a drug or combination of drugs is effective 
in pre-clinical cancer models.  Many laboratory studies define sensitivity to a specific 
drug according to its ability to decrease growth in vitro.  Indeed, several studies use 
IC50 values as the primary mode to define sensitivity. This measure provides a quick 
and robust readout that facilitates comparisons across a large panel of cancer 
models, and although such assays identify the cell lines whose growth is impacted 
by the drug, it remains less clear if such data will faithfully predict which cancers will 
respond to specific targeted therapies in a clinical setting. For example, these data 
may identify cancer cell lines that grow more slowly in response to drug. However, in 
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the clinic, this finding may still amount to disease progression, not tumor shrinkage. 
Of note, recent studies correlate responsiveness to PI3K inhibitors and MEK in vivo
with the induction of cell death (Brachmann et al., 2009; Faber et al., 2009).  Thus, 
future efforts to discover clinically useful biomarkers may benefit from 
implementation of more stringent laboratory criteria for “sensitivity”, including effects 
on both cell proliferation and apoptosis. 
5.5 Concluding Remarks 
 Over the past decade there has been a decrease in overall cancer incidence 
and death rates for both men and women in the United States.  This is largely due to 
decreases in lung, prostate and colorectal cancer in men and breast and colorectal 
cancer in women (Jemal et al., 2010).  These effects have been mediated primarily 
through increased prevention, e.g., the identification tobacco smoke as a carcinogen; 
and through better methods for early detection, e.g., the development of prostate 
specific antigen (PSA) testing, PAP smears, and mammograms. In addition, we are 
rapidly gaining a comprehensive understanding of the signaling pathways and 
molecular mechanisms that drive cancer cells, and this information has begun to 
translate into the development and approval of successful targeted therapies. 
 Despite progress in reducing cancer incidence and mortality rates and 
improving survival, 1 in 4 deaths in the United Sates are still due to cancer (Jemal et 
al., 2010).  It will remain important for at-risk patients to continue to undergo 
preventative screening, and for researchers to continue to identify new carcinogens 
and methods for early detection.  However, despite these measures, cancer will 
continue to occur in a large percentage of individuals and the demand for effective 
therapies will continue to exist in oncology.  Overall, there is still a need for the 
identification of new targets and mechanisms of resistance, and the development of 
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better drugs and diagnostics with more effective treatment regimens.  For example, 
in our recent study of gefitinib resistant NSCLC patients, no cause of resistance was 
identified for 30% percent of patients analyzed (Sequist et al., 2011).  Further, there 
is still a significant unmet need for therapeutics targeting non-kinases including RAS 
and ERBB3, as well as drugs mediating the apoptotic response.  Perhaps most 
importantly, we need a better understanding of the genetics and molecular biology of 
each unique tumor in order to effectively stratify and treat individual patients and 
move towards personalized cancer medicine.
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